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CHAPTER 1 
GENERAL INTRODUCTION -
NEPHROGENIC DIABETES INSIPIDUS : 
THE CLINICAL PICTURE - PATHOPHYSIOLOGY 
1.1 CONGENITAL NEPHROGENIC DIABETES INSIPIDUS: THE CLINICAL 
PICTURE 
1.1.1 HISTORY 
The renal type of diabetes insipidus was appreciated as a separate 
clinical entity more then 40 years ago, when it was described in-
dependently by two investigators: Forssmann (1945) in Sweden and 
Waring et al. (1945) in the United States. In the next 15 years 
about 120 additional examples of the disorder were recognized and 
studied (Kaplan et al., 1959). Families with this type of defect, 
however, had been described many years before (Mc Ilraith, 1892), 
without being distinguished from the central or neurohormonal dia-
betes insipidus. The name 'Nephrogenic Diabetes Insipidus' was 
coined by Williams and Henry (1947), who noticed that injection of 
the antidiuretic hormone in doses, sufficient to induce systemic 
side effects, could not correct the concentrating defect. Subse-
quent studies revealed biologically active hormone to be present 
in the serum (Holliday et al., 1963) and urine (Luder and Burnett, 
1954) of affected persons and lend further support to the theory of 
renal vasopressin unresponsiveness. 
Nowadays the name 'Nephrogenic Diabetes Insipidus' is used synony-
mously with the terms 'vasopressin or ADH-resistant diabetes insi-
pidus 'or 'diabetes insipidus renalis'. 
1.1.2 DEFINITION AND CLINICAL MANIFESTATION 
Congenital Nephrogenic Diabetes Insipidus (NDI) is a rare inherited 
kidney disorder, characterized by insensitivity of the distal renal 
nephron to the antidiuretic effect of vasopressin (Williams and 
Henry, 1947). As a consequence, the kidney loses its concentrating 
ability and produces large volumes of hypotonic urine (50-100 mosm/ 
kg H2O), which may lead to severe dehydration and electrolyte imba-
lance (hypematremia and hyperchloremia). The osmolar urine/plasma 
(U/P) ratio remains constantly below 1 and cannot be reversed by 
exogenous application of vasopressin. As mentioned in the initial 
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descriptions by Waring et al. (1945), Forssman (1945), and Williams 
and Henry (1947), the defect in congenital NDI is present from 
birth and therefore manifestations of the disorder emerge within 
the first weeks of life. Polyuria, as high as 500 ml per day or 
even higher in infants, and excessive thirst are the most typical 
symptoms but they may not be recognized immediately (Gautier and 
Prader, 1956; Kaplan, 1987). Instead, the clinical picture is do-
minated by signs of chronic dehydration. Irritability, poor fee-
ding and poor weight gain are often the initial symptoms. Patients 
are eager to suck, but may vomit during or shortly after the fee-
ding. Dehydration is evidenced by dryness of the skin, loss of 
normal skin turgor, recession of the eyeballs, increased perior-
bital fold depth, recession of the anterior fontanelle and scaphoid 
abdomen. Intermittent high fever is a common complication of the 
dehydrated state (Waring et al., 1945; Forssman, 1945; Williams and 
Henry, 1947; Luder and Burnett, 1954; Ellborg and Forssman, 1955; 
Kaplan et al, 1959; Schoen, I960; Lobeck et al., 1963; Schräger et 
al., 1976), particularly in the neonate and infant. Therefore, 
frequently symptoms are considered to be caused by infection and 
many children with NDI are examined thoroughly for signs of bacte-
rial, viral or parasitic disease. It is not known how many cases 
remained undiagnosed during infancy and how many children have died 
without their disease being suspected. Seizures (Schoen, I960; 
Schultz and Lines, 1975, Kanzaki et al., 1985) are rare and are 
most often seen during therapy, particularly if rehydration pro-
ceeds too rapidly. Obstipation is a common symptom in children 
with congenital NDI (Luder and Burnett, 1954; Kirman et al., 1955; 
Ellborg and Forssman, 1955; Schoen, 1960; Lobeck et al., 1963; ten 
Bensei and Peters, 1970). Nocturia and enuresis (Schoen, 1960; 
Carter and Goodman, 1963; Miller and Winston, 1966; Ramsey et al., 
1974; Monn, 1981) are frequent complaints later in childhood and it 
is not uncommon for patients to get up to drink 5 to 6 times during 
the night because of the intense thirst. 
Untreated, most patients fail to grow normally (Waring et al., 
1945; Forssman, 1945; Williams and Henry, 1947; Ellborg and Forss-
man, 1955; Hillman et al., 1958; Kaplan et al., 1959; Schoen, 1960; 
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Vest et al., 1963) and some develop mental retardation (Forssman, 
1955; Kirman et al., 1955;). Growth retardation is assumed to be 
directly related to polyuria and polydipsia (Hillman et al., 1958; 
Vest et al., 1963). Excessive fluid intake provokes anorexia and 
vomiting, which leads to malnutrition. Mental retardation, which 
can run the gamut from minor memory deficits to imbecility (Forss-
man, 1955), may be secondary to cerebral bleeding and brain damage 
caused by severe brain dehydration and hyperelectrolytemia occuring 
early in infancy (Macaulay and Watson, 1967; Kanzaki et al.,1985). 
Besides organic brain alterations, the psychological development of 
these children is influenced by a permanent craving for water and 
the urge for frequent voiding, which competes with playing and 
learning (Hillman et al., 1958). Therefore, many NDI patients are 
characterized by hyperactivity, distractibility, short attention 
span and restlessness. 
Long-lasting states of polyuria may favor the development of a me-
gacystis (Shapiro et al., 1978) and , more rarely, hydroureter and 
hydronephrosis (Silverstein and Tobian, 1961; Carter and Goodman, 
1963; Vest et al., 1963; ten Bensei and Peters, 1970), which can 
mimic lower urinary tract obstruction. 
1.1.3 DIAGNOSIS 
The family history and the observation of polyuria in a dehydrated 
infant will usually provide all evidence necessary for presuming 
the diagnosis in an affected infant. To confirm the presence of 
polyuria and to distinguish the nephrogenic form of diabetes insi-
pidus from the central form, a vasopressin test is performed by 
intranasal application of l-desamino-8-D-arginine vasopressin 
(DDAVP) (Aronson and Svenningsen, 1974; Monnens et al., 1981; Kap-
lan, 1987) which is a synthetic analogue of the natural hormone 
and is characterized by a high and prolonged antidiuretic effect 
(Richardson and Robinson, 1985). In NDI patients there is, after 
DDAVP, no increase in urine osmolality, (Usberti et al., 1980; 
Monnens et al., 1984) which remains below 200 mosm/kg H2O (normal 
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>805 irosm/kg H2O), and no reduction in urine volume or in free 
water clearance (CH2o)· 
It is still controversial as to whether the urinary excretion of 
cyclic 3',5'-adenosine monophosphate (c-AMP) can be used for dif-
ferentiating vasopressin responders from non-responders. Vasopres-
sin is considered to exert its biological effect on the kidney 
through the activation of the membrane-bound adenylate cyclase, 
which in turn converts adenosine triphosphate (ATP) to c-AMP. A 
defect in this mechanism has been suggested to be responsible for 
NDI (for detailed pathophysiological aspects see 1.2). Several in-
vestigators have observed no increase in c-AMP excretion after 
vasopressin infusion in NDI patients (Bell et al., 1974; Usberti et 
al., 1980). In these studies basal c-AMP excretion in NDI patients 
was found to be either elevated (Usberti et al., 1980) or signi-
ficantly reduced (Bell et al., 1974) compared to control subjects. 
Recently Ohzeki (1985) divided NDI in two categories with respect 
to c-AMP response, one type with and one type without an elevation 
in c-AMP excretion in response to vasopressin. A major difficulty 
in studying NDI is that urinary c-AMP excretion after vasopressin 
administration is an insensitive indicator of the renal action of 
the hormone: in a study with ADH-deficient Brattleboro rats Bia et 
al. (1979) demonstrated that physiological doses of exogenous 
vasopressin and DDAVP increase the in situ renal papillary content 
of c-AMP; however, this increase could not be detected in plasma or 
urine. These data support the concept that the physiological action 
of ADH is mediated, at least in part, through c-AMP and demonstrate 
further that changes in c-AMP following vasopressin administration 
can best be detected in vivo by measurement of in situ renal pa-
pillary c-AMP content. 
Plasma vasopressin levels are normal or slightly increased in af-
fected children (Holliday et al., 1963; Gorden et al., 1971). 
Other laboratory findings have been described in association with 
NDI, which are mainly the consequence of chronic dehydration and 
hyperelectrolytaemia. Glomerular filtration rate (GFR) is often 
slightly reduced (Cutler et al., 1962) the renal plasma flow even 
more, thus elevating the filtration fraction (Williams and Henry, 
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1947; Gorden et al., 1971). In severe dehydration states, señan 
urea and creatinine can be increased (Luder and Burnett, 1954; 
Kaplan et al., 1959; Miller and Winston, 1966; ten Bensel and 
Peters, 1970). 
Dembowski et al.(1973) reported plasma renin to be elevated in NDI 
patients. The sodium chloride content of sweat is elevated in un-
treated cases but returns to normal after saluretic treatment 
(Gautier and Prader, 1956; Lobeck et al., 1963; Plöchl and Stur, 
1965; Reimold, 1967), and the same was observed for saliva (Gautier 
and Prader, 1956). Hyperuricemia has been observed in seven adults 
with familial NDI (Cutler et al., 1962; Gordon et al., 1971), two 
of whom developed clinical gout. Urinary clearances of uric acid 
were reduced, while glomerular filtration rates were normal. This 
suggested that in adult patients, the disease may be accompanied by 
a renal tubular defect in uric acid excretion. Since children with 
familial NDI had normal serum uric acid concentrations, Gordon and 
co-workers (1971) proposed that such a defect might be an acquired 
alteration of long-lasting NDI. 
With respect to other tubular function defects in NDI, reports are 
inconsistent. Hyperaminoaciduria and decreased renal acidification 
(Kaplan et al., 1959) have been occasionally described with NDI. 
However, in the absence of dehydration or hydronephrosis, amino-
acid reabsorption rate and urinary acidification were found to be 
normal, as were the glucose reabsorption rate and the phosphate 
excretion (Williams and Henry, 1947; West and Kramer, 1955; Schoen, 
I960; Miller and Winston, 1966; Schultz and Lines, 1975; Monn, 
1981; Monnens et al., 1984). Perry et al.(1967) reported NDI asso-
ciated with cystathioninuria. 
The macroscopic anatomy of the kidney is normal (Kirman et al., 
1955). Biopsy specimens of NDI patients do not show any specific 
tubular alterations by light microscopy (Abelson, 1968; Dembowski 
et al., 1973). Dembowski and co-workers (1973) observed hypertrophy 
of the juxtaglomerular apparatus, and Abelson (1968) found that 
glomeruli were hypercellular and that glomerular hyalinization was 
sometimes present. By electron microscopy remarkable changes were 
found in both proximal and distal tubules, mainly in the mitochon-
16 
dria, which contained concentric ringed structures and myelin fi-
gures, suggesting an abnormality in mitochondrial membrane lipids 
(Abelson, 1968). However, these results may not be specific and 
have to be confirmed. Microdissection of autopsy specimens from 
children with the disease revealed shortening of proximal convo-
luted tubules (Darmady et al., 1964). It was suggested that those 
very short proximal tubular segments in NDI might be unable to 
reabsorb enough water to prevent the distal tubule from becoming 
overburdened with hypotonic filtrate. 
The primary congenital form of NDI has to be differentiated from 
the secondary or acquired form, which is much more common than the 
congenital one, but is rarely as severe. The causes are listed in 
Table 1 (Relman and Schwartz, 1958; Broberger et al., I960; Ep-
stein, I960; Bennett, 1970; Baum et al., 1974, Mooney et al., 1975; 
Singer and Forrest, 1976). 
Table 1.1; Causes of acquired or secondary Nephrogenic 
Diabetes Insipidus. 
Drug induced 
Lithium 
Tetracyclines 
Analgesic nephropathy 
Sickle cell anemia 
Hypokalemia 
Hypercalcemia 
Obstructive uropathy 
posterior urethral valves 
Juvenile nephronophtysis 
Renal dysplasia 
Chronic pyelonephritis 
Chronic uremic nephropathy 
Amyloidosis 
Sarcoidosis 
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Prognosis of NDI is largely dependent on early recognition, preven­
tion of severe dehydration and adequate nutrition during early 
childhood. 
1.1.4 GENETICS 
Most family studies have indicated that NDI is transmitted as an X-
linked recessive trait and there is reason to believe that only one 
gene is involved (Forssman, 1945; Williams and Henry, 1947; Walker 
and Ranee, 1954; West and Kramer, 1955; Carter and Simpkiss, 1956; 
Bode and Crawford, 1969). This is supported by the observations 
that male-to-male transmission does not occur and that the disorder 
is transmitted by females and fully expressed in their male off­
spring . 
Most of the female carriers of the disease are clinically asympto­
matic, although mild polydipsia and polyuria have been reported in 
a few women whose son had the disease (West and Kramer, 1955; Car­
ter and Simpkiss, 1956). 
Doubts about whether X-linked inheritance is the only type of 
transmission in NDI raised when several investigators (Robinson 
and Kaplan, 1960; Schreiner et al., 1978) described the complete 
clinical picture of the disease to occur in females. They postu­
lated an autosomal dominant inheritance with almost complete pene­
trance in the male and with reduced penetrance in the female. This 
was supported by Cannon (1955), who reported male-to-male trans­
mission on six occasions. However, critical review of these pedi­
grees (Mc Kusick, 1971) revealed that the original proposal of Χ­
Ι inked transmission is probably correct and might even fit for 
Cannon's pedigree, since all six cases of male-to-male transmission 
occurred in early generations, for which one had to rely on history 
data for the diagnosis as well as the exclusion of consanguinity. 
Recently, we were able to confirm X-liriked inheritance by demon­
strating close genetic linkage between the NDI gene and several X 
chromosomal DNA markers (Knoers et al, 1987, 1988a, 1988b, 1989), 
which allowed precise localization of the disease gene to the sub-
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telomeric region of the human X chromosome long arm, at band Xq28. 
The localization of the NDI gene and its use for reliable carrier 
detection and early (prenatal) diagnosis will be discussed in de-
tail later (chapter 2, 3, and 4). 
The prevalence of NDI is not exactly known, but the disorder is 
assumed to be quite rare, since even in large pediatric and ne-
phrology clinics it is observed infrequently (Kaplan, 1987). 
Isolated cases of the disease have encountered, with no evidence of 
affected relatives, suggesting new mutations (Ellborg and Forssman, 
1955; Gautier and Prader, 1956; Feigin et al., 1970). Bode and 
Crawford (1969) postulated that the rate of new mutations might be 
very low, and suggested that almost all patients with NDI in North 
America were descendents of the 'Ulster Scottsmen' who arrived in 
Nova Scotia aboard the ship 'Hopewell' in the 18th century. 
1.1.5 TREATMENT 
The treatment of NDI has been a problem since the original descrip-
tion of the disorder. Replacement of urinary water losses by ade-
quate supply of fluid is the most important component of therapy. 
This is easily achieved by oral intake in children and adults, but 
often requires parenteral supplementation in infants. One approach 
to reduce urine output is provision of a low solute diet to reduce 
the osmolar load and decrease the obligatory water excretion (Hill-
man et al., 1958). Initially, a diet low in sodium (1 mmol/kg/day) 
as well as protein (2 g/kg/day) was recommended (Hillman et al., 
1958; Brodehl, 1981). However, severe limitations of dietary pro-
tein may introduce serious deficiencies. Therefore, it seems pre-
ferable to prescribe a dietary restriction of sodium only. 
Treatment of NDI could be dramatically improved when Crawford and 
Kennedy (1959) and, independently, Reerink and co-workers (1959) 
introduced the use of thiazide diuretics for treatment of the dis-
order. They demonstrated that chronic administration of chloro-
thiazide could result in an increase in urine osmolality and a de-
crease in urine volume as well as thirst. Several hypotheses for 
19 
the mechanism(s) underlying the paradoxical antidiuretic effects of 
these thiazides in NDI have been reported. The observation that 
concomitant salt administration could prevent the antidiuretic 
effect of these drugs (v.d. Korst, 1965), implied that the effi-
ciency of these agents, which inhibit sodium reabsorption in the 
early distal tubule, is related to the induction of a negative salt 
balance. The resultant decrease in extracellular fluid volume with 
a normal serum sodium and, possibly, the reduction in glomerular 
filtration rate (GFR) could serve to enhance sodium and fluid reab-
sorption in the proximal tubule (Crawford and Kennedy, 1959; Ear-
ley and Orloff, 1962). In this way the sodium and water delivery to 
the distal tubules would be diminished and antidiuresis might re-
sult unrelated to the presence or effect of vasopressin. This as-
sumption was favoured by studies demonstrating that other salu-
retics, such as ethacrynic acid (Brown et al., 1966; Ramos et al., 
1967), furosemide (Reimold, 1967; von Brenndorf and Hagge, 1973) 
and spironolactones (Kowarski et al., 1966) were also effective in 
producing antidiuresis. However, Shirley et al. (1982) demonstrated 
that during chronic hydrochlorothiazide administration Brattleboro 
rats, which have hereditary diabetes insipidus due to lack of ADH, 
showed only a small reduction in the volume of fluid delivered to 
the more distal nephron segments. They suggested that the raised 
papillary osmolality, by enhancing water reabsorption at sites 
beyond the proximal tubule, makes a greater contribution to the 
antidiuresis. The thiazide induced increase in medullary osmolality 
was not explained. It was first postulated by Brown et al. (1969) 
that the antidiuresis induced by saluretics might be mediated by 
renin and angiotensin. Sodium depletion stimulates renin produc-
tion, which causes increased levels of angiotensin, and this in 
turn stimulates aldosterone release and sodium reabsorption. This 
hypothesis was supported by the observation of significantly in-
creased plasma renin levels in patients with diabetes insipidus 
(Brown et al., 1969) and NDI (Dembowski et al., 1973) which were 
treated with saluretics. In addition, it was shown that angioten-
sin can indeed produce a marked antidiuresis in NDI (Orr and Fili-
pichi, 1967). Whatever the mechanism, administration of thiazide 
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diuretics combined with a low sodium diet, will generally reduce 
polyuria by about 20-50 % of the original value (Crawford et al., 
I960). Since these drugs induce kaliuresis also (Morgan and 
Davidson, 1980), treatment should be associated with oral supple-
mentation of potassium salt in most cases. 
Several publications, but not all (Monnens et al., 1984), have 
indicated elevated prostaglandin E2 excretion in NDI patients 
(Fichman et al., 1976; Usberti et al., 1980; Blachar et al., 1980). 
It is not clear whether increased prostaglandin activity represents 
part of a primary defect in NDI or whether it is a secondary pheno-
menon, for instance due to elevated ADH levels. It is generally 
accepted that ADH stimulates medullary prostaglandin E2 production 
(reviewed by Beck and Dunn, 1981), but the significance of this 
regulation is still unclear. Whatever the cause, the observation of 
increased prostaglandin E2 excretion in NDI formed the basis for 
treatment of the disease with prostaglandin synthesis inhibitors, 
such as indomethacin (Fichman et al., 1976; Usberti et al., 1980; 
Blachar et al., 1980; Monnens et al., 1984; Libber et al., 1986; 
Rasher et al., 1987), iboprufen (Fichman et al., 1978) and acetyl-
salicylic acid (Monn, 1981). Administration of these agents ap-
peared to have a beneficial effect on urinary output in NDI, espe-
cially when combined with hydrochlorothiazide (Blachar et al., 
1980; Monnens et al., 1984; Rasher et al., 1987). However, the 
mechanisms by which prostaglandin synthesis inhibitors cause a 
reduction in urine volume in NDI are not exactly known. Despite 
many contradictions in the literature there is evidence that pros-
taglandins antagonize the ADH-sensitive adenylate cyclase in the 
collecting tubule (reviewed by Beck and Dunn, 1981) and that, on 
the other hand, inhibitors of prostaglandin synthesis potentiate 
the effect of ADH on collecting duct cells. Inhibitors of prosta-
glandin synthesis enhanced ADH-induced water permeability in the 
toad bladder (Albert and Handler, 1974; Ray and Morgan, 1981) and 
rat medullary collecting duct (Jackson et al., 1980a) and in-
creased maximum urine osmolality in dogs (Anderson et al., 1975) 
and humans (Beri et al., 1977) given vasopressin. Lum et al.(1977) 
demonstrated that administration of indomethacin to rats enhanced 
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accumulation of medullary cyclic AMP in réponse to a submaximal 
dose of ADH. They were careful to establish that the effect of 
indomethacin was not due to an inhibition of phospodiesterase, 
that degrades c-AMP to its 5' monophosphate counterpart. This is an 
important observation, since indomethacin does inhibit phospho-
diesterase in vivo (Newcombe et al., 1974) and in vitro (Beri et 
al., 1977). Since c-AMP mediates the hydroosmotic effect of ADH, it 
was postulated that the increase in tissue c-AMP level could be 
responsible for the enhanced physiologic response to the hormone. 
However, the presence of ADH is not essential for the antidiuretic 
effect of prostaglandin synthesis inhibitors, since it was demon-
strated that these agents also reduced urine output in Brattleboro 
rats, known to lack ADH (Stoff et al., 1981) and in humans with 
central diabetes insipidus (Fichman et al, 1978). Alternatively, 
mechanisms independent of ADH might underly the water reabsorption 
and decrease in urine volume observed after administration of pros-
taglandin synthetase inhibitors. In animals treated with indo-
methacin increased papillary solute concentrations, acting as a 
driving force for enhanced water reabsorption, have been demon-
strated (Ganguli et al., 1977; Passmore et al., 1980; Stoff et al., 
1981). The increased papillary tonicity can be ascribed either to a 
reduction in papillary solute wash-out resulting from decreased 
blood flow (Passmore et al., 1980; Ganguli et al., 1981; Stokes, 
1981) or to an increase of sodium chloride transport in the thick 
ascending limb and collecting ducts (Stokes, 1981; Stoff et al., 
1981; Libber et al., 1986). 
Finally, a reduction in glomerular filtration rate (GFR) might con-
tribute to the antidiuretic action of indomethacin and other pros-
taglandin synthesis inhibitors (Monnens et al., 1984 ; Rasher et 
al., 1987). However, a significant fall in GFR response to prosta-
glandin synthesis inhibitors has not been observed in all patients 
with NDI (Libber et al., 1986). 
Whatever the explanation, indomethacin and other prostaglandin syn-
thetase inhibitors have proven to be an important gain in the 
treatment of NDI, especially in young children. However, numerous 
reports of possible systemic and renal adverse effects due to the 
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treatment with prostaglandin synthesis inhibitors have appeared in 
the literature (Walshe and Venuto, 1979; Tan et al., 1979). 
Dyspepsia (Boardman and Hart, 1967) and peptic ulcer are known side 
effects of chronic administration of indomethacin, aspirin or Ibu-
profen. Vomiting, abdominal distention, melaena, and necrotising 
enterocolitis have been observed in relation with indomethacin 
therapy (Harinck et al., 1977). Tan et al. (1979) reported the 
occurrence of acute renal failure during indomethacin therapy in a 
patient with chronic pyelonephritis. 
An alternative therapeutic approach was recently proposed by Alon 
and Chan (1985). In view of the previously reported efficacy of the 
potassium sparing diuretic amiloride as treatment for lithium-
induced NDI in rats (Feuerstein et al., 1981) and humans (Battle et 
al., 1983), they tested the combination amiloride-hydrochloro-
thiazide in 2 NDI patients, with encouraging results. This alter-
native therapy regimen will be discussed in detail in chapter 7. 
1.2 NEPHROGENIC DIABETES INSIPIDUS: PATHOPHYSIOLOGY 
1.2.1 INTRODUCTION 
In order to understand the pathophysiological mechanism(s) involved 
in NDI, it is necessary to consider the physiological effects of 
vasopressin (antidiuretic hormone, ADH) on the kidney. Vasopressin 
subserves a number of different functions in the mammalian kidney. 
These include: 
(1) Modulation of water (and solute) transport (Hebert and Andreo-
li, 1984; Tornita et al., 1986; Abramow et al., 1987; Hebert et 
al., 1987; Sands et al., 1987; Sands and Knepper, 1987). 
(2) Vasoconstriction (Andrews and Brenner, 1981; Kreisberg, 1983; 
Schlondorf, 1987) (see 1.2.5). 
(3) Stimulation of prostaglandin synthesis (Kirschenbaum et al., 
1982; Ardaillou et al., 1985; Wuthrich and Valloton, 1986) 
(see 1.1.5). 
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(4) Inhibition of renin secretion. 
It is well established that vasopressin inhibits renin secre­
tion in a variety of species including man (Keeton and Camp­
bell, 1981; Share, 1988). The inhibition of renin secretion is 
related to the dose of vasopressin and can be produced by ele­
vations in plasma vasopressin within the physiological range. 
The mechanism of inhibition of renin secretion by vasopressin 
is not well understood. Possible actions that have been sug­
gested to result in inhibition of renin secretion include 
volume expansion, vasoconstriction, altered renal handling of 
sodium, decreased renal sympathetic nerve activity, release of 
atrial natriuretic peptide from the heart or a direct action of 
vasopressin in the juxtaglomerular apparatus (Keeton and Camp­
bell, 1981; Itoh et al., 1987; Share, 1988). 
Each of these functions is mediated by either one of two receptor 
subtypes, termed V^ and V2 receptors (Micheli et al., 1979). These 
distinct receptor subtypes have been recognized on the basis of 
both functional (Micheli et al., 1979; Jard, 1988) and pharmacolo­
gical criteria (Stassen et al., 1982; Jard, 1988; Kinter et al., 
1988; Liard, 1988; Thibonnier, 1988). The д^  receptor is functio­
nally connected to a phosphoinositide specific phospholipase and to 
Ca 2 + mobilization, while the V2 receptor is coupled to the membrane 
bound adenylate cyclase. In addition, V^ and V2 receptors can be 
distinguished by their molecular sizes (Crause et al., 1984). For 
the most part, the V2 receptor subserves epithelial functions, such 
as water and solute transport, while the V^ receptor subserves 
funtions on cells of mesenchymical origin, such as vasoconstric­
tion and stimulation of prostaglandin synthesis. Recently, the 
existence of both V^ and V2 receptors in the principal cells of the 
rabbit cortical collecting tubule was demonstrated (Bumatowska-
Hledin and Spielman, 1989). The physiological significance of this 
dual receptor system is not exactly known. In amphibian bladders 
interactions between the Vj^  receptor-mediated phosphoinositide 
pathway and the V2 receptor-mediated c-AMP pathway have been des­
cribed (Schlondorff and Levine, 1985). These studies demonstrate 
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that direct activation of proteine kinase С (which is an interme­
diate in the phosphoinositide pathway) by phorbol esters suppres­
ses ADH induced water flow. Based on the assumption that V^ and V2 
receptors exist in the same renal epithelial cells, Schlondorff and 
Levine (1985) postulated that V-^ receptor occupancy serves to down-
regulate the V2 receptor response. However, it is not known if 
these observations in amphibian bladders also apply to the mamma­
lian kidney. There is strong evidence for the existence of extra­
renal V2 receptors (Chapter 5 and 6; Kobrinski et al., 1985; Bichet 
et al., 1988). However, the localization of these vasopressin re­
ceptors remains to be elucidated. Extrarenal V-^ receptors have been 
identified on liver (Tolbert et al., 1980; Fishman et al., 1987), 
vascular smooth muscle cells (Fox et al., 1987; Stassen et al., 
1987) and on platelets (Thomas et al., 1983; DiTullio et al., 
1985; Vittet et al., 1986; Inaba et al., 1988). 
In this chapter the first function of ADH , the modulation of water 
(and solute) transport, will be discussed in detail. This is the 
all-important action by which ADH controls the volume and osmola­
lity of the urine, in order to maintain water balance. Before dis­
cussing this action of vasopressin (1.2.4), two processes that are 
involved in the regulation of water excretion by ADH, are des­
cribed: (1) ADH release (1.2.2) and (2) The build-up and mainte­
nance of a cortico-papillary interstitial osmotic gradient by the 
renal countercurrent system (1.2.3). In section 1.2.5 a brief des­
cription of the extrarenal effects of ADH will be given. Section 
1.2.6 describes an animal model that phenotypically closely resem­
bles human hereditary NDI. Finally, in section 1.2.7., the mecha­
nisms are discussed, which might underly the unresponsiveness to 
vasopressin in NDI. 
1.2.2 ANTIDIURETIC HORMONE RELEASE 
Arginine vasopressin (AVP) or antidiuretic hormone (ADH) is a 
cyclic nonapeptide, produced in the supraoptic and paraventricular 
nuclei in the hypothalamus, transported along the axons of the 
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supraopticoneurohypophyseal tract, and stored in the posterior 
pituitary (Scharrer and Scharrer, 1954). Under normal circum­
stances ADH release is primarily regulated by changes in plasma 
osmolality (Robertson, 1987), which are monitored by osmorecep-
tive mechanisms. These osmoreceptors are multiple in nature and are 
localized both centrally and peripherally (Sladek and Armstrong, 
1985). The system regulating the osmolality-dependent release of 
ADH is very sensitive and reacts to changes in plasma osmolality 
as small as 1 % (Dunn et al., 1973). 
Vasopressin release, however, can also occur in the absence of 
changes in plasma osmolality (Schrier et al., 1979). The nonosmotic 
stimuli for vasopressin secretion generally are related to changes 
in either total blood volume or in the distribution of extracellu­
lar fluid, such as in shock, blood loss due to trauma, cardiac 
failure, liver disease, and adrenal insufficiency. In addition, 
physical pain, emotional stress and certain drugs (i.e. nicotine) 
influence the release of А Ш . The nonosmotic regulation of ADH is 
modulated mainly by baroreceptors within the great vessels in the 
thorax (Gauer and Henry, 1963), stretch receptors in the atria of 
the heart (Henry et al., 1956), and possibly also by carotid sinus 
chemoreceptors (Share and Levy, 1966) (see also review in Share, 
1988). This nonosmotic pathway is less sensitive than the osmotic 
one (Dunn et al., 1973). Recently, interest has been focussed on 
possible central mediators of vasopressin release that could serve 
to affect the release of the hormone in response to osmotic as well 
as nonosmotic stimuli (Sklar and Schrier, 1983), for instance bio­
genic amines, prostaglandins, and angiotensin II. In addition, 
atrial natriuretic factor (ANF) was found to have a central inhi­
bitory effect on the basal secretory rate of vasopressin in sheep 
(Lee et al., 1987) and in the rat (Poole et al., 1987). 
1.2.3 BUILD-UP AND MAINTENANCE OF A CORTICO-PAPILLARY INTERSTITIAL 
OSMOTIC GRADIENT. 
The existence of an osmotic gradient in the renal medullary inter-
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stitium provides the driving force for water reabsorption from the 
ADH-responsive portions of the distal nephron (the collecting duct 
system). The build up and maintenance of such a gradient is depen­
dent on the normal functioning of the so-called renal countercur-
rent system (Kuhn and Ryffel, 1942). Following a short description 
of the functional unit of the kidney, the principles of this coun-
tercurrent mechanism will be discussed in this section. 
The functional unit of the kidney is the nephron. There are at 
least two types of nephron: the outer cortical (or superficial) and 
the juxtamedullary. These and their relationship to the major zones 
of the kidney are shown in Fig. 1. 
Fig.1.1 : 
Ivo nepron populations, 
superficial, (SF) and 
juxtamedullary (ЛМ) are 
depicted. The major 
nephron segments are 
labeled as follows: РСГ = 
proximal convoluted tu­
bule; Ж = pars recta; 
DTIH = descending thin 
limb of Henle; ΑΪΤΗ = 
ascending thin limb of 
Henle; ΜΓΑΙΗ = medullary 
thick ascending limb of 
Henle; СГАШ = cortical 
thick ascending limb of 
Henle; DCT = distal con­
voluted tubule; CS = con­
necting segment; OCT = 
cortical collecting tu­
bule; СМСГ = outer me­
dullary collecting tu­
bule; IMCT = inner 
medullary collecting 
tubule; PCD = papil­
lary collecting duct. 
(Taken f rem Jacobson, 
H.R. - Functional seg­
mentation of the mam­
malian nephron. Am.a. 
Physiol. 241, 1981, 
F203-F218, with permis­
sion) 
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Each nephron is build up of a glomerulus, surrounded by Bowman's 
capsule, then successively a proximal tubule, the straight portion 
(pars recta) of which reaches through the outer strip of the outer 
medulla, a descending limb of Henle's loop, a thin ascending limb 
of Henle's loop (in the juxtamedullary nephrons only), a thick 
ascending limb of Henle's loop, reaching through the outer medulla 
into the cortex, a distal tubule and a collecting tubule. A jux­
tamedullary nephron is distinguished from an outer cortical 
nephron by the following characteristics: it has a long loop of 
Henle which turns within the inner medulla; and its postglomerular 
blood supply gives rise to the vasa recta, which course through the 
outer and inner medulla (Fig. 2). 
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Fig. 1.2: 
Comparison of the anatomy and blood supplies of outer cortical and 
juxtamedullary nephrons. (Adapted from Pitts, R.F. - Hiysiology of the 
kidney and body fluids, 3d ed., 1974, Year Book Medical Publishers, 
Chicago) 
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These anatomic features have important functional consequences, as 
will be seen later. 
Urine is concentrated with relative little expenditure of metabolic 
energy by the renal countercurrent mechanism, a complex interaction 
between the loops of Henle, the medullary interstitium and the 
collecting tubule. The two fundamental processes of the counter-
current mechanism, countercurrent multiplication (a) and counter-
current exchange (b) will be delineated in the following. 
(a) Countercurrent multiplication 
In 1942 the functional significance of the loop of Henle was pro-
posed when Kuhn and Ryffel developed the concept of countercurrent 
multiplication for urine concentration. The core of this hypothesis 
is that a small difference in osmotic gradient (the so-called 
single effect) at any point between fluid in opposite directions in 
two parallel tubes, connected in a hairpin manner, can be multi-
plied many times along the length of these tubes. Support for this 
hypothesis was subsequently given by Hargitay and Kuhn (1951), Wirz 
et al. (1951), and Gottschalk and Mylle (1959), who stated that the 
requirements for countercurrent multiplication are readily satis-
fied in the loop of Henle. The ascending and descending limbs of 
Henle's loop exhibit a countercurrent flow and have a striking 
difference in membrane permeabilities that are essential for this 
process. The descending limb is highly permeable to water and to a 
lesser degree to solutes (Kokko, 1970). Both the thin and the thick 
ascending limbs are water-impermeable. The thick ascending limb 
possesses an active Cl~ transport system (Burg and Green, 1973; 
Rocha and Kokko, 1973), which provides an initial step in counter-
current multiplication. The principle of this process is shown in 
Fig. 3. Initially, the fluid in the descending and ascending limb 
and in the interstitium is isoosmotic to plasma, similar to that 
delivered from the proximal tubule (a). The active transport of 
NaCl in the thick ascending limb dilutes the tubule fluid in this 
segment and concentrates the medullary interstitium. Then the 
tubule fluid in the descending limb equilibrates to the hypertonic 
medullary interstitium (b). As urine passes through the tubules, 
29 
and NaCl transport in the ascending limb continues, the initial 
step is multiplied by the countercurrent flow arrangement of the 
loops of Henle (c - f ). 
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Fig 1.3: 
Countercurrent multiplication system in the loop of Ifenle. 
(Adapted f rem P i t t s , R.F. - Physiology of the kidney and body 
fluids, 3d ed., 1974, Year Book Medical Publishers, Chicago) 
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Ultimately, a high osmolar concentration difference between the 
cortico-medullary junction and the hairpin loop at the tip of the 
papilla is generated. This form of countercurrent multiplication, 
which depends on active CI- transport, occurs primarily in the 
thick ascending limbs of Henle's loop, which are located in the 
outer medulla (short loops). 
However, in the thin ascending limbs, located in the inner medulla 
(long loops), where the greatest rise in osmolality occurs, an ac-
tive CI- transport process has not been identified (Imai and 
Kokko, 1974; Jamison, 1987). Considering this, Kokko and Rector 
DISTAL TUBULE 
CORTEX 
OUTER 
MEDULLA 
INNER 
MEDULLA 
NaCI 
LOOP OF HEN LE COLLECTING 
TUBULE 
Fig. 1.4; 
Schematic representation of the passive urinary concentration 
msdhanism, according to the model of Stephenson (1972) and Kokko 
and Rector (1972). (Taken from Jamison, R.L., Maffly, R.H. - Ihe 
urinary concentrating mechanism. N.Engl.J.Med. ¿95, 1976, 1059-
1066, with permission) 
31 
(1972) and simultaneously Stephenson (1972) proposed a model which 
provides two spatially distinct sites for countercurrent multipli­
cation: an active step in the outer medulla and a passive step in 
the inner medulla, the latter involving urea recycling. In this 
model, active transport of sodium chloride by the thick ascending 
limb creates the osmotic gradients that allow water reabsorption to 
occur in the collecting tubule. This results in a concentrated 
solution of urea, which is delivered to the inner medullary col­
lecting duct, where, in the presence of ADH (see 1.2.4), urea is 
reabsorbed and trapped in the inner medulla. High urea concen­
trations extract water from the descending limb and provide for 
NaCl concentration gradients across a salt-permeable water-imper­
meable thin ascending limb (Fig. 4) . Reabsorption of NaCl thus 
provides the passive step in countercurrent multiplication. Many 
alternative models were put forward (review in Jamison, 1987). 
(b) Countercurrent exchange (Berliner et al., 1958; Fig. 5) 
This process occurs in the vasa recta. Like the loop of Henle, the 
vasa recta form a counterflow system, in which blood flows in oppo­
site directions in descending and ascending segments. In the des­
cending vasa recta water leaves the blood and solute enters. A 
progressive rise in osmolality in the descending blood ensues, 
reaching the maximum at the hairpin turn. As blood ascends again, 
it gains water and loses salt to the progressively less hypertonic 
medullary interstitium. This arrangement minimizes the degree to 
which blood flow through the medulla decreases the hyperosmolality 
of that area. Thus, countercurrent exchange is a crucial factor in 
the maintenance of a corticopapillary osmotic gradient. A relative­
ly low blood flow through the medulla is essential for maintaining 
the hyperosmolality of the medullary interstitium. In this regard, 
it is interesting to note that, at least in the rat, ADH decreases 
inner medullary blood flow (Zimmerhackl et al., 1985). This effect 
of ADH is mediated, at least in part, by the д^  receptor, since an 
antagonist of the Vj^  action of ADH prevented the vasopressin-in-
duced decrease in medullary blood flow. Recently, Kiberd and co-
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Intentitium 
Cortex 
Medulla 
Ascending capillary limb 
·- Passive diffusion of solute (NaCl + urea) 
»• Passive diffusion of HjO 
Fig. 1.5; 
Principle of countercurrent exchange in the vasa recta capillaries. In 
the descending capillary limb, solute enters and water leaves the ca­
pillary down concentration gradients, tending to reduce interstitial 
osmolality. These processes are reversed in the ascending limb, thereby 
preserving the interstitial gradient. (Adapted fron Pitts, R.F. - Phy­
siology of the kidney and body fluids, За ed., 1974, Year Book Medical 
Publishers, Chicago) 
workers (1987) suggested that the ADH-induced decrease in inner 
medullary blood flow is also mediated in part by its antidiuretic 
(V2 receptor) action. Using fluorescence videomicroscopy, they 
demonstrated that during infusion of a V2 inhibitor with ADH or 
the inhibitor alone, medullary blood flow did not fall, but re­
vealed instead a tendency to increase with time. The V2 inhibitor 
did not inhibit the pressor effect of vasopressin. 
1.2.4 MODULATION OF WATER AND SOLUTE TRANSPORT BY VASOPRESSIN. 
1. Modulation of water transport. 
The regulation of water absorption across the collecting duct sys­
tem, defined as the late distal tubule and the collecting ducts, 
is the most important function through which ADH determines the 
concentration of urine (DeSousa, 1984). When ADH levels are unde-
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tectable, these portions of the nephron are relatively impermeable, 
and hypotonic urine, leaving the ascending limb of Henle's loop, is 
excreted. In the presence of ADH, these portions of the nephron 
become more permeable to water, and the tubular fluid is concen-
trated as it passes down the collecting system and equilibrates 
with the hypertonic medullary interstitium. 
Much has been learned about the mechanism by which vasopressin 
induces this effect. An review of the cellular events secondary to 
vasopressin action was recently published by Abramow et al.(1987). 
The initial step involves the binding of ADH to a specific receptor 
located at the outer surface of the basolateral membrane of respon-
sive epithelial cells. The vasopressin-receptor complex activates 
the enzyme adenylate cyclase, which catalyzes the formation of 
cyclic adenosine monophospate (c-AMP) from adenosine triphosphate 
(ATP). c-AMP, in turn, activates a protein kinase which initiates a 
sequence of events ultimately resulting in increased permeability 
of the apical (luminal) membrane. 
In the following, the steps resulting in increased production of c-
AMP, the terminal events at the luminal membrane and finally, the 
intermediate steps triggered by c-AMP, will be discussed in more 
detail. 
Events leading to increased production of c-AMP. 
Receptors 
It is generally accepted that the renal vasopressin receptors, 
which mediate the antidiuretic action of the hormone, are functio-
nally coupled to the membrane bound adenylate cyclase, an enzyme 
catalyzing the formation of cyclic adenosine monophosphate (c-AMP ) 
from its precursor adenosine triphosphate (ATP) (Orloff and Hand-
ler, 1962; Anderson and Brown, 1963; Grantham and Burg, 1966; 
Rajerison et al., 1974). Vasopressin-sensitive adenylate cyclase 
activity has been identified in several segments of the mammalian 
nephron (the cortical and medullary segments of the collecting duct 
and, in some species [rat, mouse, but not man], the ascending limb 
of Henle's loop) (Morel, 1981; Morel et al., 1987). Cellular adeny-
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late cyclase activity was found to be proportional to the degree of 
hormone binding to receptor sites (Rajerison et al., 1974; Butlen 
et al., 1978; Hechter et al., 1978a). The renal vasopressin recep-
tor belongs to the V2 receptor subtype. Specific vasopressin bin-
ding sites have been characterized on renal membranes from various 
mammalian species, including man (Bockaert et al., 1973; Rajerison 
et al., 1974; Roy et al., 1975; Butlen et al., 1978; Hechter et 
al., 1978a, 1978b; Guillon et al., 1982). Vasopressin binds to a 
single class of high affinity receptors. The dissociation constant 
varies depending on the species from 0.4 nM (rat) to 10-20 riM (pig) 
(Jard, 1983). Binding is specific, time-dependent, reversible and 
saturable. Recently, Steiner and Philips (1988) published the bin-
ding characteristics of vasopressin receptors specifically for a 
basolateral membrane preparation of rat renal epithelia. Their data 
confirm the existence of high-affinity, highly specific V2 recep-
tors on these membranes. Vasopressin receptor down-regulation has 
been reported to occur in response to physiologically elevated le-
vels of vasopressin (Roy et al., 1981; Steiner and Philips, 1988). 
The molecular structure of the renal V2 receptor and of the effec-
tor system in renal membranes is unknown at present. The molecular 
size of the V2 receptors in bovine and rat kidney membranes was 
determined, using the technique of radiation inactivation (target 
size analysis) (Crause et al., 1984). The inactivation of membrane 
bound renal V2 receptors by ionizing radiation was determined by 
measuring the decay of the specific binding capacity for vasopres-
sin. Molecular sizes of approximately 95 kDA (rat kidney) and 108 
kDA (bovine kidney) were found. This technique gives the molecular 
weight (Mr) of a functional complex rather than the molecular 
weight of a subunit. To identify renal vasopressin receptor pro-
teins, Fahrenholz and co-workers (1985, 1988) developed a series of 
photoreactive vasopressin analogues, with a photoreactive aryl-
azido-group in position 4 or 8 of the vasopressin amino acid se-
quence. These arylazido analogues can be activated by flash photo-
lysis with ultraviolet light. When activated, these ligands bind to 
the receptor and induce a permanent stimulation of renal vasopres-
sin-sensitive adenylate cyclase. In photoaffinity experiments with 
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tritium labelled ligands, a membrane protein from bovine kidney or 
rat kidney medulla with an apparent molecular mass of 30,000 was 
preferentially labelled and to a lesser degree also a protein with 
of M
r
 60,000. The results suggested that a 30,000 M
r
 protein is 
the binding subunit of the renal V2 receptor. In addition, these 
studies provide evidence for a second subunit of the renal V2 re­
ceptor with a M
r
 of about 60,000. 
Guanine nucleotide binding proteins 
Recent progress has been made into the mechanisms of the modulation 
at the transduction step between V2 receptor occupancy and the ac­
tivation of adenylate cyclase. In the last decade, it has become 
clear that all membrane receptors interact with effector systems to 
modulate the intracellular levels of a second messenger via the in-
terroediacy of members of a family of membrane-bound guanine nucleo­
tide binding proteins (G-proteins or N-proteins). Rodbell and co­
workers (1971), whilst studying the ability of the peptide hormone 
glucagon to stimulate adenylate cyclase activity in hepatocytes, 
were the first to demonstrate a specific requirement for guanine 
nucleotides in hormonal function. Since these pioneering studies, a 
considerable number of G-proteins has been discovered, some of 
which have been purified and cloned (Bimbaumer et al., 1987; 
Lochrie and Simon, 1989). The G-proteins are heterotrimers. Their 
subunits are designed α, β, and y in order of decreasing molecular 
mass. The a-subunit carries the nucleotide binding site. Alpha-sub-
units clearly differ among the members of the family. The β chains 
are nearly identical, whereas the 7 subunits show some differences. 
Recent reviews (Stryer and Bourne, 1986; Spiegel, 1987; Gilman, 
1987) give a detailed description of the mechanism of activation of 
G-proteins. Fig.6 summarizes the current view on this process. In 
the resting state, the G-protein exists in the holomeric form with 
GDP bound to the nucleotide binding site of the a-subunit. Hormone-
receptor binding produces a change in receptor-G-protein interac­
tion, allowing GTP to replace GDP on the α subunit. Release of GDP 
must obviously preceed the binding of GTP, because there is only 
one site for nucleotide binding on the a-subunit. Release of GDP 
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appears to be the rate limiting step in G-protein activation/inac-
tivation. With GTP in the nucleotide binding site and in the pre­
sence of Mg 2 + (Iyengar and Bimbaumer, 1981; Bimbaumer et al., 
1985), the holomeric G-protein dissociates into an active a-subunit 
with bound GTP and free β/γ units. This active o-subunit is then 
able to modify the activity of the effector system (in this case: 
adenylate cyclase). Hydrolytic cleavage of the terminal phosphate 
from the bound GTP by intrinsic GTP-ase activity deactivates the e-
subunit and in this GDP bound form is then able to reassociate with 
β/γ subunits to restore the inactive G-protein. 
Receptor + agonist 
t l 
Activated receptor-agonist 
complex 
Fia. 1.6; 
The role of GTP binding and hydrolysis in the activation and deactiva-
tion of a typical G-protein. (Taten from Milligan, G. - Techniques 
used in the identification and analysis of function of pertussis 
toxin-sensitive guanine nucleotide binding proteins. Biochem.J. 225. 
1988, 1-13, with permission) 
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Two bacterial toxins can interrupt the signal transduction cycle at 
specific stages. Pertussis toxin uncouples receptors from G-pro-
teins thereby abolishing signaling (Jakobs et al., 1984), while 
cholera toxin inhibits GTP-ase activity which enhances signaling 
(Gill, 1977). 
Two G-proteins are involved in the activation of adenylate cyclase 
activity, which either activate (Gs) or inhibit (G^) adenylate 
cyclase, when the activating (Rg) or inhibiting (R¿) receptor is 
occupied respectively (Bimbaumer et al., 1986). Vasopressin uses 
the activating pathway while alpha-2-adrenergic agents, for in-
stance, are inhibitory by occupying R^ (Edwards and Celiai, 1988). 
Both G-proteins have been purified and their molecular structures 
have been characterized (Northup et al., 1983a, 1983b; Bokoch et 
al., 1983; Codina et al., 1984). They are structurally very simi-
lar, albeit not identical, proteins (reviews in: Bimbaumer et 
al., 1986; Gillman, 1987; Spiegel, 1987). Activation of both pro-
teins through hormone-receptor interaction involves the sequential 
steps of GTP-GDP exchange, magnesium addition, and dissociation of 
their respective α, ß/y subunits. The GTP-bound dissociated form of 
the α subunit combines with the adenylate cyclase, to result in 
either stimulation or inhibition. Besides a direct inhibitory ac­
tion of the α subunit of Gj^  with adenylate cyclase, an indirect 
action of its β subunit to inhibit G
s
 subunit dissociation has been 
suggested (Katada et al., 1984a, 1984b; Bimbavmer et al., 1986). 
However, the exact mechanism by which G·^  proteins affect adenylate 
cyclase remains unknown (Pingoud et al., 1988). 
Receptor-independent activation of G
s
 and Gj^  can occur using non-
hydrolysable guanyl nucleotide analogs or the fluoride ion (Nor­
thup et al., 1983a, 1983b; Katada et al., 1984a, 1984b; Bimbaumer 
et al., 1985). 
Direct stimulation of adenylate cyclase, independent from receptor 
and G-protein has been demonstrated using forskolin (Nadler et al., 
1986) . 
Interactions with vasopressin at the level of G-proteins have been 
shown for prostaglandins (Nadler et al., 1986) and bradykinin 
(Schuster, 1985). Both substances are generated in the kidney and 
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inhibit the hydroosmotic response to vasopressin. In the isolated 
rabbit cortical collecting tubule, exogenous PGE2 reversibly in-
hibited the hydroosmotic response to vasopressin and to cholera 
toxin, but not the response to forskolin (Nadler et al., 1986). 
This sets the site of vasopressin-prostaglandin interaction at the 
level of the G-protein. The mechanism of action of bradykinin has 
been explored using a similar experimental approach (Schuster, 
1985). 
c-AMP breakdown 
The intracellular concentration of c-AMP is determined not only by 
its rate of formation, but also by its rate of breakdown, which is 
catalyzed by a c-AMP phosphodiesterase. Inhibitors of this phospho-
diesterase, such as theophylline (Orloff and Handler, 1967), ami-
nophylline or chlorpropamide (Chaudhuri and Winer, 1970) can po-
tentiate the effect of ADH on renal tubules, probably by inhibi-
ting c-AMP breakdown. c-AMP serves as em intracellular mediator of 
ADH and induces the ultimate functional change, the increase in 
water permeability of the tubular epithelium (Orloff and Handler, 
1967; Dousa, 1973). Exogenous c-AMP added to the tissue mimics the 
hydroosmotic effect of ADH both in renal tubules and in amphibian 
bladders, such as the toad bladder (Orloff and Handler, 1962; 
Grantham and Burg, 1966). 
Terminal events at the luminal membrane. 
The mechanisms by which c-AMP, formed within the cell under the in-
fluence of vasopressin, produces the change in water permeability 
have not been fully elucidated. By current view the final event may 
be the insertion of water permeable patches into the apical (lumi-
nal) membrane (Muller and Kachadorian, 1984; Hays et al., 1987; 
Brown, 1989). 
In amphibian bladder, Chevalier and co-workers (1974) and later 
others (Kachadorian et al., 1977) have demonstrated by freeze-
fracture electronmicroscopy that an increased transepithelial flow 
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of water, induced by neurohypophyseal hormones (including vaso­
pressin) , is associated with the appearance of intramembranous 
particle (ШР) clusters (or aggregates) within the apical membranes 
of responsive cells. The same phenomenon was demonstrated in mamma­
lian collecting ducts also (Harmanci et al., 1978). In both amphi­
bian and mammalian epithelia, the number of particle aggregates per 
unit of area of apical membrane was proportional to the concentra­
tion of ADH (Kachadorian et al., 1977; Harmanci et al., 1978, 
1980). Consistently, only a few particle aggregates were visua­
lized in renal papillas of Brattleboro rats, known to lack ADH, 
until these animals were infused with the hormone (Brown and Orci, 
1983). Furthermore, IMP clusters are absent from the apical mem­
branes of collecting duct cells from mice with severe NDI (Brown 
et al., 1985). Based on the aforementioned observations, it is 
generally assumed that particle aggregates constitute or are close­
ly associated with ADH-elicited water channels. Initially, these 
IMPs were attributed to the aggregation of intramembranous par­
ticles that were present under basal conditions. Recently, it was 
indicated that, at least in amphibian bladders, these particles 
originate from elongated cytoplasmic vesicles, termed aggregophores 
(Muller and Kachadorian, 1984). Upon stimulation with ADH, aggre­
gophores fuse with the apical membrane and after fusion, a propor­
tion of the aggregophore·s component of particle aggregates is 
translated into the lipid bilayer of the apical membrane. Removal 
of ADH causes detachment of aggregophores from the apical membrane 
and a rapid decrease in tissue water permeability (Muller and 
Kachadorian, 1984). To gain more information about the molecular 
weight of vasopressin-induced proteins in aggregophores that sub­
sequently appear on the cell surface, Harris and co-workers (1988) 
have used, in the toad bladder, a combination of lactoperoxidase-
induced ionidation and horseradish peroxidase density shifting of 
endocytosed vesicles. The density-shift technique is a method for 
increasing the density of vesicles so that they can be more easily 
separated from other cell components by centrifugation. A number of 
candidate bands have been identified by gel electrophoresis and 
monoclonal antibodies are being prepared against specific bands. 
40 
Aggregophores have not been visualized in collecting duct cells of 
the mammalian kidney. The details of the АШ-elicited apical mem­
brane events in the mammalian collecting duct are less clear. The 
current hypothesis on this proces was recently published by Brown 
(1989). In the collecting duct, the intramembranous particle (IMP) 
clusters, presumed to represent water channels, are located in pits 
coated by clathrin, a unique membrane protein, in the apical sur­
face of principle cells. The principal cell is one of two major 
cell types in the collecting duct (the other one being the inter­
calated cell). Principal cells account for 60-70% of the cells in 
the cortical collecting duct and are characterized by extensive 
basilar membrane infoldings. Vasopressin induces a large increase 
of both IMP clusters and coated pits in collecting ducts of Bratt-
leboro rats (Brown and Orci, 1983). Exocytotic insertion of the 
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Fig. 1.7i 
Diagram of the proposed pathway of water channel recycling in collec­
ting duct principal cells. IMPs that are believed to represent water 
channels are concentrated in clathrin-coated pits at the cell surface 
and are endocytosed in coated vesicles. These vesicles are rapidly de-» 
coated, and while their fluid-phase content may eventually reach mul­
tivesicular lysoscmes, water channels themselves may escape degradation 
and be recycled back to the apical membrane. 
(Taken from Brcwn, D. - Membrane recycling and epithelial function. Am. 
J. Ehysiol. 256, 1989, F1-F12, with permission) 
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water channels into the apical membrane is responsible for in-
creasing the permeability to water (Abramow et al., 1987). As long 
as vasopressin is present, these water channels are continuously 
recycled to and from the apical membranes via coated pits (Fig. 7). 
Upon vasopressin withdrawal, the endocytotic pathway takes prece-
dence, so that the coated patches, containing the water channels 
are rapidly removed from the apical membrane and reside on vesicles 
in the cytoplasm (Brown et al., 1988). Evidence for this latter 
event was given by Strange et al.(1988) by studying the endocytosis 
of horseradish peroxidase in perfused cortical collecting tubules. 
They demonstrated increased apical membrane endocytosis via coated 
pits to occur following removal of ADH from the peritiibular bathing 
medium. They suggested that the rapid decline in the permeability 
of the cortical collecting duct, which takes place in response to 
ADH withdrawal, is mediated by retrieval of water permeable mem-
brane via coated pits. Thus, sufficient evidence exists that cla-
thrin-coated pits are involved in cluster internalization in the 
kidney. However, the mechanisms underlying this process at the 
molecular level are completely unknown at present. 
Intermediate events triggered by c-AMP. 
The intermediate steps between the generation of c-AMP and the 
final permeability changes in the apical membrane, described above, 
are not well defined. 
Protein kinase 
It is widely accepted that c-AMP activates a protein kinase, and 
that this activation is a prerequisite for its effect on water per-
meability (Jard and Bastide, 1970; Schlondorff and Franki, 1980; 
Edwards et al., 1980). Initially, it was believed that this c-AMP 
dependent protein kinase controls the phosphorylation of critical 
cellular proteins (Dousa and Valtin, 1976). This reaction could be 
reversed by phosphoprotein phosphatase-catalyzed dephosphorylation 
of the effector proteins. However, these putative effector phospho-
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proteins have proven extremely difficult to identify. Reports of 
specific c-AMP dependent phosphorylation of apical cell membrane in 
bovine renal medulla (Schwartz et al., 1974) have not been con­
firmed. A 50,000 dalton protein, found on toad urinary bladders and 
initially linked to the cellular actions of ADH and c-AMP, appeared 
to be identical to the regulatory subunit of protein kinase itself 
(Malkinson et al., 1975). It is now known that this c-AMP dependent 
protein kinase (cA-PK) exists as two major isoenzymes (Lohmann and 
Walter, 1984) , the cA-PK type I and type II, which differ in the 
structural and functional properties of their cAMP-binding subunit 
(Rj and К ц , respectively). Recently, Gapstur and co-workers 
(1988), utilizing the technique of photoaffinity labeling with 
32P-labelled 8-azido-adenosine 3'5'-cyclic monophosphate (N3-8[32P] 
cAMP) as a probe, provided direct evidence that cAMP binds to the 
regulatory subunits Rj and Rjj of cAMP dependent protein kinase in 
medullary collecting duct and thick ascending limb of the rat kid­
ney. Their analysis showed incorporation of Ыз-8[32Р]сАМР into two 
bands (M
r
=40,000 and M
r
=55,000) that co-migrated with the cA-PK 
subunits Rj and К ц . 
Cytoskeleton 
Microtubuli and microfilaments might be involved in the hydroos-
motic response to ADH and c-AMP (Kachadorian et al., 1979). Both 
organelles are important components of the cytoskeleton and are 
involved in the maintenance of cell shape and in the movement of 
cell components (Dedman et al., 1979). Several drugs that are 
known to disrupt microtubular systems, such as colchicine and 
vinblastine, inhibit the action of vasopressin and c-AMP on water 
permeability in the toad urinary bladder (Taylor et al., 1973). 
Cytochalasin, a microfilament inhibitor, has similar effects 
(Kachadorian et al., 1979). This suggests that the integrity of the 
cytoskeleton in epithelial cells is required in cellular action of 
ADH subsequent to c-AMP generation. However, the precise role of 
microtubules and microfilaments in the hydroosmotic response to 
vasopressin has yet to be delineated. 
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Calcium-calmodulin 
Calcium has been suggested to modulate the antidiuretic action of 
ADH. Although there are some conflicting reports (Hardy, 1978; 
Dillingham et al., 1987; Taylor et al., 1987), the current view is 
that an increase in cellular calcium inhibits water flow in А Ш -
sensitive epithelia. Both a pre- and post c-AMP mechanism has been 
implicated. Cellular calcium concentrations modulate the activity 
of the adenylate cyclase. In medullary collecting duct cells of the 
rat, Teitelbaum and Beri (1986) demonstrated that lowering of cel­
lular calcium by EGTA was associated with an increment in cAMP 
generation, while an elevation of cellular calcium by the calcium 
ionophore A23187, was consistently associated with an impairment in 
the response to vasopressin. On the other hand, a post c-AMP mecha­
nism, most likely related to an effect of Ca 2 + (in complex with 
calmodulin) on microtubular structures, has been proposed (Dilling­
ham et al., 1987). 
Atrial natriuretic factor 
Atrial natriuretic factor (ANF) has been shown to counteract the 
antidiuretic effect of vasopressin (Dillingham and Anderson, 1986; 
Nonoguchi et al., 1988). However, the level of interaction between 
the two hormones remains to be elucidated. Both a site proximal 
(Dillingham and Anderson, 1986) and distal (Naray-Fejes-TÓth et 
al., 1988; Nonoguchi et al., 1988) to the generation of c-AMP have 
been suggested. 
2. Modulation of solute transport. 
In addition to the modulation of water transport in the collecting 
duct system, vasopressin increases urea transport in the terminal 
part of the mammalian inner medullary collecting duct (Morgan and 
Berliner, 1968; Sands et al., 1987). It has been demonstrated that 
the vasopressin-mediated increase in urea permeability in this 
nephron segment also results from activation of adenylate cyclase 
and generation of intracellular c-AMP (Star et al., 1988). This 
urea transport is important for the urinary concentrating mechanism 
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because it supplies nearly all of the urea that accumulates in the 
medullary interstitium (Sands and Knepper, 1987) (see 1.2.3: coun-
tercurrent multiplication). 
In various non-human kidneys (rat; mouse; rabbit), vasopressin sti-
mulates reabsorption of NaCl in the thick ascending limb of Henle's 
loop (Sasaki and Imai, 1980). Such a process could have an impor-
tant role in the renal concentrating mechanism, by enhancing solute 
accumulation in the medullary interstitium. In these species the 
presence of a vasopressin-sensitive adenylate cyclase in the medul-
lary portion of the thick ascending limb has been demonstrated 
(Imbert-Teboul et al., 1978; Morel, 1981). In humans, however, this 
nephron segment appeared to be completely unresponsive to ADH 
(Morel, 1981). Therefore, it seems unlikely that the transport of 
NaCl in the human thick ascending limb is modulated by ADH. 
In summary, the antidiuretic effect of vasopressin can be attri-
buted mainly to its influence on the water permeability of the 
collecting duct system. ADH-induced increase in urea permeability 
of the terminal inner medullary collecting duct and, in some 
species (but not in man), the increase in NaCl reabsorption abet 
the build-up of a cortico-papillary osmotic gradient and thus 
improve the concentrating ability of the kidney. 
1.2.5 EXTRARENAL EFFECTS OF VASOPRESSIN 
In addition to its effects on the kidney, vasopressin exerts a 
panoply of extrarenal functions, the most important of which will 
be discussed here. 
1. Cardiovascular regulation 
Vasopressin has a significant role in cardiovascular regulation. 
Reduction in blood volume and blood pressure are potent stimuli 
for vasopressin release (see 1.2.2). Vasopressin is a potent vaso-
constrictor in vitro. As early as 1922, Krogh and Rehberg, in 
studies of the circulation in the web of the frog's foot, recog-
nized the great vasoconstrictoring potency of an extract of the 
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posterior pituitary. They suggested that this gland might secrete a 
substance which circulates in the blood at a very low concentration 
and which contributes to the maintenance of the tonicity of the 
capillaries. The actions of ADH on the cardiovascular system are 
very complex. An excellent review on this subject was recently pu­
blished by Share (1988). Vasopressin causes vasoconstriction in 
most vascular beds (Nakano, 1973) , with the exception of the cere­
bral vessels (Lasoff and Altura, 1980). The receptors responsible 
for the action of vasopressin on vascular smooth muscle are clas­
sified as V^ receptors (see 1.2.1). 
In addition to its vasoconstrictoring effect, vasopressin acts on 
the hart in two important ways. It decreases both the heart rate 
and the cardiac output (Lee et al., 1988). These cardiac effects 
result from very small, physiologically relevant elevations in 
plasma vasopressin levels (Aylward et al., 1986; Ebert et al., 
1986; Tipayamontri et al., 1987). The mechanisms by which these 
effects on the heart are achieved are in part understood. Baro­
reflex mechanisms appear to contribute to lowering cardiac output 
in conscious dogs, since the fall is greatly blunted following 
sinoaortic baroreceptor denervation (Montani et al., 1980). As a 
result of the reflexively mediated decrease in heart rate and car­
diac output secondary to a rise in peripheral vascular resistance, 
blood pressure in the intact organism does not change until vaso­
pressin concentrations reach the upper end of the physiological 
range (Montani et al., 1980). High vasopressin concentrations are 
seen in situations of severe volume insufficiency, such as dehy­
dration, hemorrhage, adrenal insufficiency or septic shock. In 
these circumstances, vasopressin has an important role in main­
taining blood pressure (Laycock et al., 1979; Andrews and Brenner, 
1981). When blood volume is reduced, vasopressin acts to maintain 
blood pressure in conjunction with the sympathetic nervous system 
and the renin-angiotensin-aldosterone system (McNeill, 1983; 
Berecek et al., 1985). In addition, there is evidence for inter­
actions between vasopressin and other systems in the regulation of 
cardiac function: Vasopressin stimulates the synthesis of prosta­
glandin І2 (PGI2), a potent vasodilatator, from vascular smooth 
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muscle (Hassid and Williams, 1983), and PGI2 in turn modulates the 
vasoconstrictoring action of vasopressin (Glänzer et al., 1982). 
Vasopressin causes relaxations of isolated basilar arteries of the 
dog, an effect that is dependent on the presence of endothelium 
(Katusic et al., 1984). This is due to a vasopressin induced re-
lease of a humoral factor termed endothelium derived relaxing fac-
tor (EDRF), which relaxes the underlying vascular smooth muscle. 
However, in the femoral artery, endothelial cells do not modulate 
the contractile response to vasopressin. The latter finding con-
firms that vasopressin acts as a potent endothelium-independent 
constrictor on peripheral blood vessels. The differential effects 
of vasopressin on cerebral and peripheral arteries support the 
interpretation that increased levels of circulating vasopressin, 
for instance during hemorrhage or septic shock, favor the redis-
tribution of blood from the periphery to the cerebral circulation 
and help to maintain cerebral blood flow (Katusic et al., 1984). 
Interactions between vasopressin and atrial natriuretic factor 
(ANF) have been described. In addition to its natriuretic and 
diuretic properties, ANF has a potent vasodilatory effect (DeBold, 
1985), opposite to the vasoconstriction induced by vasopressin. 
Based on experiments with rat aortic smooth muscle cells, Nambi and 
co-workers (1986) suggested that the vasoconstrictor activity of 
vasopressin might partly involve inhibition of ANF-receptor-media-
ted vascular relaxation, through inhibition of accumulation of the 
second messenger, cyclic guanosine monophosphate (c-GMP). However, 
the exact molecular mechanism(s) of interaction between vasopres-
sin and ANF remains to be elucidated. 
Finally, the gonadal steroid hormones can substantially affect the 
cardiovascular actions of vasopressin. Thus, the pressor respon-
siveness is much greater in male than in randomly cycling female 
rats (Crofton et al., 1986). The mechanisms responsible for the 
differences in pressor responsiveness between males and females 
are uncertain, but could involve actions of the gonadal steroids on 
the central nervous system and the peripheral vasculature. 
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2. Platelet aggregation 
In platelets vasopressin has been shown to induce shape change, 
aggregation and release reaction (Haslam and Rosson, 1972). The 
platelet vasopressin receptor appeared to be of the V-^ subtype, 
since vasopressin induced aggregation was potently inhibited by V^ 
antagonists, whereas a selective V2 agonist failed to induce aggre-
gation of human platelets (Thomas et al., 1983; DiTullio et al., 
1985). In the circulation, however, vasopressin concentrations are 
in the pM range (Share, 1988), which means that physiologically 
only a fraction of platelet vasopressin receptors are occupied 
and/or activated. Therefore, it remains to be established whether 
or not this vasopressin receptor has any functional significance in 
terms of platelet pathophysiology. 
3. Glycogenolysis 
Vasopressin elicits a glycogenolytic and gluconeogenetic response 
in rat hepatocytes (Hems and Whitton, 1973; Tolbert et al., 1980). 
This effect is mediated also by vasopressin receptors of the V^ 
subtype. The rat liver V^ receptor has recently been purified and 
characterized (Fishman et al., 1987). This receptor is a glyco-
protein and has a molecular weight of approximately 68,000 under 
reducing conditions and 58,000 under non-reducing conditions. 
4. Miscellaneous 
Vasopressin increases corticotropin release by the adenohypophysis 
(Gillies et al., 1978), has mitogenic effects on several cell types 
(Whitfield et al., 1970; Hunt et al., 1977; Rozengurt et al., 
1979), and increases the firing rate of various neuronal groups in 
the brain (MÜhlethaler et al., 1982). 
In addition, vasopressin has several effects on animal behaviour. A 
number of experiments in rats have shown that vasopressin maintains 
learned avoidance behaviour, reverses amnesia and supports other 
aspects of memory function (De Wied 1969). Vasopressin and vaso-
pressin analogues appear to be involved in various aspects of me-
mory consolidation both in experimental animals and humans. A 
review on this last subject is given by De Wied (1976). 
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Vasopressin and its V2 agonist l-desainino-8-D-arginine vasopressin 
(DDAVP) are known to produce an increase in blood clotting factor 
VIII-, von Willebrand factor (vWF)- and tissue-type plasminogen 
activator levels in man (Manucci et al., 1975). It has been sug­
gested that these effects are mediated through stimulation of ex­
trarenal V2 receptors. This hypothesis was supported by the obser­
vation that FVIII, vWF (Kobrinski et al., 1985; Bichet et al., 
1988) and plasminogen activator (Knoers et al., 1990) were not 
stimulated by DDAVP in patients with nephrogenic diabetes insi­
pidus. A detailed discussion on these extrarenal effects and ab­
sence of these effects in NDI patients will follow later (Chapter 
5 and 6). 
1.2.6 ANIMAL MODEL FOR N.D.I. 
A mutant mice strain, DI severe, has been described (Naik and 
Valtin, 1969) which is a phenocopy of human NDI and is charac­
terized by an inherited, vasopressin-resistant defect of urine 
concentration. Biochemical studies in these mice have helped to 
delineate the specific defects for the ADH resistance in this ani­
mal model. Dousa and Valtin (1974) measured the activity of ade­
nylate cyclase in cell-free membrane preparations from renal me­
dulla in the absence of hormone (basal activity), in the presence 
of ΙΟ - 6 M vasopressin for maximal stimulation, and after nonspeci­
fic stimulation with fluoride in DI severe mice. The activity of 
adenylate cyclase, when stimulated maximally by saturating doses 
of vasopressin, was found to be significantly lower in DI severe 
mice than in control animals. The basal and fluoride-stimulated 
activities of renal medullary adenylate cyclase in these mice did 
not significantly differ from those in normal mice, indicating that 
there is no major deficiency in the catalytic capacity of adenylate 
cyclase itself. Furthermore, the adenylate cyclase of DI severe 
mice could be stimulated by vasopressin, and the dose required to 
elicit one-half of the maximal stimulation was not significantly 
different from the dose in controls. These findings suggest that 
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the receptor has normal affinity for vasopressin. In addition, c-
AMP phosphodiesterase and c-AMP dependent protein kinase activi-
ties were not different from those of normal mice. 
More recently, Jackson et al (1980b), in experiments carried out in 
microdissected tubules, found the functional unresponsiveness of DI 
severe mice to vasopressin is mainly the result of the inability of 
the collecting tubules to increase intracellular c-AMP levels in 
response to vasopressin. This inability was assumed to result part-
ly from lower stimulation of adenylate cyclase in the medullary 
collecting tubule, but mainly from abnormally high c-AMP phospho-
diesterase activity in the medullary collecting tubule, since in-
hibition of c-AMP phosphodiesterase with l-methyl-3-isobutyl xan-
thine (MIX) caused a significant increase of vasopressin-induced c-
AMP levels. In addition, ADH-stimulated adenylate cyclase was found 
to be significantly reduced in the medullary thick ascending limb 
of Henle's loop. Based on these observations, they suggested that 
the decreased adenylate cyclase, demonstrated in the studies of 
Dousa and Valtin (1974), was due to decreased activity of this 
enzyme in the thick ascending limb rather than in the collecting 
ducts. The decrease in adenylate cyclase activity in the thick as-
cending limb of hereditary DI severe mice might represent the bio-
chemical basis of a second abnormality in the concentrating abili-
ty of these animals (i.e., a defect in gradient formation). 
However, since an ADH-sensitive adenylate cyclase has not been 
detected in the human thick ascending limb (Morel, 1981), the 
relevance of these findings for hereditary NDI in humans is un-
known. 
Recently, Kusano et al. (1986) reported that deficient ATP, the 
substrate for c-AMP generation by adenylate cyclase, is not a 
limiting factor accounting for defective ADH-stimulated c-AMP 
generation in medullary collecting tubules of DI severe mice. This 
is consistent with the hypothesis that the defective cellular ac-
tivity of vasopressin in these mice is due to elevated levels of 
c-AMP phosphodiesterase, resulting in increased c-AMP degradation. 
Brown et al. (1985) argued that the defect could be localized at 
other sites of the metabolic cascade as well. They demonstrated 
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lack of intramembranous particle cluster aggregation in collecting 
ducts of mice with hereditary DI. 
Very recently, Braun and Stallone (1989) reported a second good 
animal model that can be exploited to gain better understanding of 
the mechanism(s) underlying NDI. This model is a strain of White 
Leghorn domestic fowl that appeared to possess all the characteris-
tics of hereditary NDI. The defect in these birds is inherited as 
an autosomal recessive trait. 
1.2.7 POSSIBLE MECHANSIMS UNDERLYING THE UNRESPONSIVENESS TO ANTI-
DIURETIC HORMONE IN NDI 
At present, the pathogenesis of the concentrating defect in pa-
tients with NDI is totally unknown. In contrast to patients with 
central diabetes insipidus, no defects in ADH synthesis or release 
have been found in any of the NDI patients (Williams and Henry, 
1947; Luder and Burnett, 1954; Cannon, 1955; Holliday et al., 
1963). In addition, anti-ADH-antibodies are absent from the plasma 
of these patients (Forssman, 1945; Robertson and Scheidler, 1981). 
Following Williams and Henry (1947), disturbances in the generation 
and/or maintenance of an osmotic gradient (see 1.2.3) can not be 
responsible for the defective concentrating ability in 'true' NDI. 
Consequently, familial NDI appears to be exclusively due to renal 
resistance to the action of ADH. Theoretically, in view of the 
aforementioned physiological aspects of ADH action, the defect in 
NDI could be located at any of the steps from vasopressin-binding 
to the final effect of the hormone on the luminal membrane. 
Initially, attempts were made to determine whether the primary 
abnormality is located proximal or distal to c-AMP generation, 
utilizing the urinary excretion of c-AMP after administration of 
vasopressin as an indicator of the renal action of the hormone 
(see also 1.1.3). Urinary levels of c-AMP in NDI patients did not 
increase in response to ADH in some reports (Bell et al., 1974; 
Usberti et al., 1980). On the other hand, a significant increase in 
c-AMP excretion after vasopressin has been reported by others 
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(Ohzeki et al., 1984). Based on these observations, Ohzeki (1985) 
divided NDI into two types with regard to the intrarenal site of 
ADH resistance. One type was considered to have a defect in the 
production of c-AMP in renal tubular cells, and the other in the 
reception of the c-AMP signal. However, it has been demonstrated 
that urinary c-AMP excretion does not reflect intracellular c-AMP 
levels accurately (Bia et al., 1979). Proesmans et al. (1975) uti-
lized the administration of exogenous c-AMP to define the exis-
tence of defects distal to c-AMP generation. However, since the 
intravenous or intramuscular administration of c-AMP is followed by 
rapid inactivation of this compound by extrarenal tissues, a lack 
of response to exogenous c-AMP need not imply the presence of a 
distal defect. Thus, in spite of intensive study, direct evidence 
for a defect either proximal or distal to c-AMP generation in pa-
tients with NDI is lacking. 
Defects proximal to the formation of c-AMP would include: 
(1) Defective vasopressin binding due to absence or abnormality of 
the renal V2 receptor. 
(2) Decreased adenylate cyclase activity due either to defective 
activation and/or functioning of the guanine nucleotide binding 
proteins involved in adenylate cyclase activity, or due to a 
defect in the enzyme per se. 
(3) Increased c-AMP phosphodiesterase levels, which would induce 
abnormally high degradation of c-AMP to AMP. 
Until now, it has not been possible to directly measure vasopres-
sin-binding, adenylate cyclase activity and its stimulation with 
vasopressin in human kidney specimens of NDI patients. An abnor-
mally active c-AMP phosphodiesterase has been reported in DI severe 
mice (Jackson et al., 1980b). However, it should be recalled that, 
although the hereditary disease in mice has functional features 
similar to those of the hereditary disease in man, it is not cer-
tain that the defect in cellular action of ADH in human NDI is 
identical or analogous to that in the experimental disease. 
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Defects distal to the generation of c-AMP could include: 
(1) Inhibition or defect of c-AMP dependent protein kinase . 
(2) Disruption of microtubules and/or microfilaments. 
(3) Abnormalities in intréunembranous particle aggregation. 
(4) Alterations in calcium homeostasis. 
(5) Alterations in cellular prostaglandin metabolism. 
Of all these potential defects distal to c-AMP generation only the 
abnormality in intramembranous particle aggregation has been ob-
served in the mouse NDI model (Brown et al., 1985). 
Whether lack of intramembranous particle aggregation is involved in 
the concentrating defect in NDI patients remains to be elucidated. 
Since disruptions of the cytoskeleton and alterations in calcium 
homeostasis are expected to involve not only the kidney they can be 
readily excluded as possible candidates for the defect underlying 
NDI. The presumed role of prostaglandins in the pathogenesis of NDI 
has been discussed in detail in 1.1.5. For further discussion of 
the possible defect(s) in NDI, we refer to chapter 8. 
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1.4 AIM OF THE STUDY. 
Reliable detection of women heterozygous for X-1inked Nephrogenic 
Diabetes Insipidus is of considerable importance, because this 
offers the possibility of treating affected males very early in 
life. Early diagnosis of affected males is essential because, 
without treatment, severe brain dehydration may lead to mental 
retardation. Female NDI carriers are clinically asymptomatic but 
may demonstrate a defect in urinary concentrating ability. However, 
normal concentrating ability does not rule out the possibility that 
the female is a carrier of the disease. 
The fact that the NDI gene lies on the X chromosome offers possi-
bilities for identification of carriers and, possibly, prenatal 
diagnosis, with use of DNA recombinant technology. Therefore, we 
employed DNA linkage analysis in 11 Dutch NDI families (Chapter 2, 
3, and 4). 
There is evidence that the renal insensitivity to vasopressin in 
NDI is due to a defect in the renal V2 receptor. It has been pos-
tulated that the V2 receptor defect is not confined to the distal 
nephron, but is egually expressed in extrarenal tissues. In order 
to test this hypothesis and with the aim of getting more insight 
into the pathogenesis of NDI, we studied the hemodynamic, coagu-
lation, and fibrinolytic responses to the synthetic V2 analogue 1-
desamino-8-D-arginine vasopressin (DDAVP), effects assumed to be 
mediated through extrarenal V2 receptor activation, in NDI patients 
and compared these responses to those found in normal controls 
(chapter 5 and 6). In addition, the fibrinolytic responses to DDAVP 
were examined in female NDI carriers in order to find out whether 
the reaction to DDAVP infusion could be of value in discriminating 
carriers from non-carriers (Chapter 5). 
Since the responses to DDAVP in one of our patients appeared to be 
completely different from those found in the other patients, we 
assumed that this patient must suffer from a variant type of NDI. 
His case is presented in chapter 6. 
The most effective treatment of NDI at the moment, indomethacin 
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combined with hydrochlorothiazide, has many disadvantages, such as 
hypokalemia due to prolonged use of hydrochlorothiazide and several 
other side effects inherent to long-term treatment with indo-
methacin. Based on a previous study suggesting the possible effi-
cacy of the combination amiloride-hydrochlorothiazide in the treat-
ment of NDI, we compared the effects of this alternative combina-
tion to those of the indomethacin-hydrochlorothiazide regimen 
(chapter 7). 
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2.1. ABSTRACT 
In five families with X-linked nephrogenic diabetes insipidus 
(NDI), linkage studies with the DNA marker DXS52, defined by probe 
Stl4, have shown no recombination with a maximum combined lod score 
score of 6.40. These results assign the NDI gene to the subtelome-
ric region of the X chromosome long arm. This finding should faci-
litate identification of carriers and should also be helpful in 
finding the NDI gene itself. 
2.2. INTRODUCTION 
Nephrogenic diabetes insipidus (NDI) is a rare X-linked disorder, 
characterized by insensitivity of the renal tubule to antidiuretic 
hormone. Affected males usually present soon after birth with poly-
uria, severe dehydration, fever, and failure to thrive. Without 
treatment some patients die and of those surviving, many are men-
tally retarded. The biochemical defect underlying NDI is still 
unknown. 
Female carriers are clinically asymptomatic but may demonstrate a 
defect in urinary concentrating ability [1]. This allows detection 
of a certain proportion of carriers. However, normal renal concen-
trating ability does not rule out the possibility that the female 
is a carrier of the disease [2]. 
The regional assignment of the NDI gene on the human X chromosome 
is not yet known, although a previous study has excluded genetic 
linkage with the Xg blood group, which is located in the Xp22.3-
Xpter region [3]. We performed linkage studies with various X-
linked restriction fragment length polymorphisms (RFLPs), i.e. 
genetic markers that can be detected by restriction endonuclease 
digestion, electrophoretic separation of DNA fragments and hybri-
dization with cloned DNA sequences, so-called probes [4]. 
Here we report on the results of linkage studies in five families 
with NDI employing the DXS52 marker, which is defined by the Stl4 
probe [5]. 
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2.3. MATERIALS AND METHODS 
Subjects 
Included in the study were five families with NDI from the 
Netherlands. Pedigrees are shown in Fig. 1. 
In affected males, diagnosis was confirmed by the lack of increase 
of urine osmolality after administration of the synthetic vaso­
pressin analogue, l-desamino-8-D-arginine-vasopressin (DDAVP). 
Maximal urine osmolalities that could be achieved after DDAVP 
infusion were 51-198 mosmol/kg (mean 104 mosmol/kg). 
Twelve affected males and 58 unaffected family members were 
available for RFLP analysis. 
DNA analysis 
Blood samples (40 ml) from affected and unaffected family members 
were collected in EDTA and stored at -20oC until use. Total human 
DNA was isolated by the following method: 20 ml of blood was added 
to 200 ml lysis buffer (0.32 M sucrose, 5 iriM МдСІ2, 10 mM Tris-HCl; 
pH 7.5) and centrifuged at 2,800 g for 10 min at 40C. The superna­
tant was carefully aspirated, taken up in 50 ml of the same lysis 
buffer and the centrifugation was repeated. The pellet of white 
cell nuclei was resuspended in 9 ml of 75 mM NaCl, 24 mM EDTA (pH 
8) . To this was added 450 μ.1 10% sodium dodecyl sulfate (SDS) and 
500 μΐ of 3 mg/ml proteinase К (Boehringer, Mannheim) in 0.2 M 
Tris-HCl (pH 8.0), 0.2 M EDTA, 0.5% sodium dodecyl sulfate and the 
mixture was incubated overnight at 50oC. To remove proteins, the 
digest was extracted with an equal volume of phenol, followed by 
extraction with phenol/chloroform (1:1) and subsequently with pure 
chloroform. The DNA was precipitated with 0.75 volume of isopro-
panol and 0.01 volume of 100 μΐ 5 M NaCl and washed twice with 70% 
ethanol. The DNA samples were resuspended in 10 mM Tris-HCl (pH 
7.5), 1 mM EDTA and stored at 40C. The DNA (10 дд) was digested 
overnight at 50oC with the restriction enzyme TaqI (Boehringer, 
Mannheim), separated on 0.9% agarose gel, denatured in 0.25 N HCl 
and transferred to Gene screen plus filters (MEN research products, 
Boston) in 0.5 M NaOH, 1.5 M NaCl by the Southern Blot method [6]. 
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Fig 2.1 : Pedigrees of five families with 
X-linked NDI A-Ε. Closed squares = affected 
males; circles with central dot = obliga­
tory carriers. Numbers refer to the length 
of allelic restriction fragments detected 
with the Stl4 probe. In family C, NDI co-
segregates with the 4.8-kb allele. Absence 
of this allele in possible carriers may in­
dicate that these females do not carry the 
NDI gene. 
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After transfer, filters were rinsed in 50 mM phosphate buffer and 
irradiated with ultraviolet light for 2 min. Filters were pre-
hybridized for 4-6 h at 650C in 0.5 M sodium phosphate buffer (pH 
7.3), containing 7 % SDS, 1 mM EDTA, and 500 μg sonicated herring 
sperm DNA. The Stl4 probe (kindly provided by J.L. Mandel, Stras­
bourg) (200-400 ng) was radiolabeled with 5 μΐ 32P-dCTP to a 
specific activity of 2.5 χ IO8 cpm^g using the primer elongation 
method [ 7 ]. The radiolabeled probe was denatured by heating to 
100oC. Subsequently it was hybridized overnight at 650C to DNA 
bound to the filters in 10 ml 0.5 M sodium phosphate buffer (pH 
7.3), containing 7 % SDS, 1 mM EDTA and 250 дд sonicated herring 
sperm DNA. After overnight hybridization the filters were rinsed 3 
times for 5 min and once for 30 min, respectively, in 40 mM sodium 
phosphate buffer (pH 7.3) and 1 % SDS at 650C. The filters were 
then exposed to a Kodak X-Omat S film with two intensifying screens 
for 1-3 days at -70oC. 
Linkage analysis 
Linkage analysis was carried out using the LINKAGE program [8] on 
an IBM compatible personal computer. This program uses the method 
of maximum likelihood to calculate lod scores (log of odds of lin­
kage versus independent assortment) [9] at selected recombination 
fractions for each pedigree and also permits summing lod scores at 
each value for individual pedigrees. The frequency of the mutant 
NDI allele in females was taken as 1 in 10 5 and a mutation rate of 
5xl0~6 was assumed. For linkage analysis, biochemical abnormalities 
in possible female carriers were not taken into account. 
2.4. RESULTS 
When human genomic DNA is digested with the restriction enzyme 
TaqI, the Stl4 probe reveals a complex polymorphic banding pattern 
with up to 10 allelic fragments ranging from 6.6 to 3.4 kb and se­
veral constant bands [5]. In all our five families the obligate 
carriers of NDI were informative for the Stl4 marker, that is, hy-
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bridization with the Stl4 probe revealed restriction fragments of 
differing size on their X chromosomes, which permitted distinction 
between the X chromosome bearing the NDI gene and the normal chro­
mosome. Affection status as well as genotypes of all individuals 
tested are shown in Fig.l. In each family, specific (but mostly 
different) Stl4 alleles cosegregate with the disease. For example, 
in family E, the TaqI 4.0 kb allele was always associated with the 
NDI gene through three generations. This disease-specific allele 
was not found in the unaffected male offspring. The lod score for 
this family was 1.03 at a recombination fraction of 0.00 (Table 1). 
Table 2.1 Lod scores for linkage relationship between NDI and DXS52 in 
five families at different values of reocribination fraction 
Recombination fraction , θ Za (P 
0.00 0.01 0.05 0.10 0.20 0.30 0.40 
Family A 
Family В 
Family С 
Family D 
Family E 
0.44 
1.26 
2.77 
0.90 
1.03 
0.43 
1.24 
2.75 
0.89 
1.01 
0.40 
1.14 
2.65 
0.81 
0.93 
0.35 
1.02 
2.46 
0.72 
0.82 
0.26 
0.76 
1.97 
0.52 
0.60 
0.16 
0.50 
1.35 
0.30 
0.36 
0.08 
0.24 
0.61 
0.09 
0.14 
0.44 
1.26 
2.77 
0.90 
1.03 
0.00 
0.00 
0.00 
0.00 
0.00 
Totals 6.40 6.32 5.93 5.37 4.11 2.67 1.16 6.40 0.00 
toximum likelihood estimation of the lod score. 
Fecombination fraction a t Z. 
No crossovers were observed between NDI and St l4 i n any of t h e f ive 
fami l ie s . The combined maximum lod score was 6.40 a t a recombina-
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tion of 0 % (confidence limits: 0-10 %) : that is, the odds were 
10 6· 4 :1 in favor of linkage. 
2.5. DISCUSSION 
The application of RFLPs as genetic markers has led to a detailed 
map of the human X chromosome [10]. This enables localization of 
almost any X-linked disorder if informative families are available 
for linkage studies. Localization of the defective gene and iden-
tification of closely linked polymorphic markers are useful for 
carrier detection and prenatal diagnosis especially if the bio-
chemical defect underlying the disease is not known. 
So far, linkage analysis with DNA probes has been succesful in 
determining the chromosomal localization of a great number of 
disorders, including Duchenne muscular dystrophy [11], Norrie's 
disease [12], X-linked retinitis pigmentosa [13] and adrenoleuko-
dystrophy (AID) [14]. 
As to NDI, a previous study has excluded linkage of the NDI locus 
with the Xg blood group, located in the Xp22.3-pter region [3]. The 
present study demonstrates linkage between the gene responsible for 
NDI and the DXS52 locus, defined by probe Stl4, which maps at Xq28 
[5]. The calculated maximum combined lod score of 6.40 at a re-
combination fraction of 0 % is highly significant. These results 
assign the NDI locus to the subtelomeric region of the X chromosome 
long arm in the vicinity of factor VIII, AID, glucose-6-phosphate-
dehydrogenase and the colour blindness genes (Fig.2). Whether the 
gene is distal or proximal to the DXS52 locus will be determined by 
further studies. 
Until now only a certain proportion of NDI carriers could be iden-
tified by clinical testing owing to the fact that the heterozygote 
females do not always manifest a defect in renal concentrating 
ability [15]. The regional assignment of the gene responsible for 
NDI provides a closely linked marker, which may be of use for iden-
tification of carriers. This is exemplified for one family in Fig. 
1. In addition, mapping of the NDI locus may pave the way towards 
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showing the position of various 
gene loci. The proposed site of 
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isolating the gene itself. 
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3.1 ABSTRACT 
Ten families with Nephrogenic Diabetes Insipidus (NDI) have been 
analysed for restriction fragment length polymorphisms (RFLPs). A 
search for linkage was performed using various chromosome-specific 
single-copy DNA probes of known regional assignment to the human X-
chromosome. Close linkage was found between the disease locus and 
the markers DXS52, DXS15, DXS134 and the F8 gene. This result 
assigns the NDI gene to the subtelomeric region of the long arm of 
the X chromosome. The regional localization of the gene by the 
identification of closely linked markers should have repercussions 
for genetic counselling and prevention in NDI families. 
3.2 INTRODUCTION 
Nephrogenic Diabetes Insipidus (NDI) is a rare inherited disorder, 
which was first described by Waring et al. (1945). Pedigree ana-
lyses indicate that the disease is transmitted by a single X-lin-
ked recessive gene (Williams and Henry, 1947; Bode and Crawford, 
1969), although other modes of inheritance have been suggested 
(Robinson and Kaplan, I960). 
NDI is characterized by renal resistance to the antidiuretic action 
of vasopressin. As a consequence, the kidney loses its ability to 
concentrate urine. The disorder becomes manifest early in infancy, 
with polyuria, periods of life-threatening dehydration, fever, ano-
rexia, vomiting and failure to thrive. Without treatment, mental 
retardation may develop due to brain dehydration. The gene involved 
has not yet been identified and the molecular pathogenesis of NDI 
is unknown. However, it has been suggested that the defect under-
lying vasopressin resistance is located beyond the intracellular 
formation of cyclic AMP (Proesmans et al., 1975). Females are 
clinically asymptomatic, but in 60 % of them a relative inability 
to concentrate urine can be demonstrated (Carter and Simpkiss, 
1956; Schoen, 1960). 
The subregional localisation of the NDI gene on the human X-chro-
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mosome is unknown. Close linkage to the Xg-locus has been excluded 
(Bode and Miettinen, 1970). Recently, we have obtained evidence for 
linkage between the NDI gene and marker DXS52 (Stl4), which is lo­
cated at Xq28 (Knoers et al., 1987, 1988; see also Davies et al., 
1987). In order to extend these preliminary observations and to 
search for useful diagnostic markers in the vicinity of the di­
sease gene, linkage studies were performed in ten Dutch NDI fami­
lies, employing seven DNA markers from the long arm of the X-
chromosome. 
In the present report our linkage data, which enable precise lo­
calization of the NDI gene on the human X-chromosome, are summa­
rized. In addition, our results provide compelling evidence that 
NDI is due to a single X-linked recessive gene defect. 
3.3 MATERIALS AND METHODS 
Subjects 
Ten NDI families from the Netherlands were included in the study. 
Pedigrees are presented in Fig.l. Nineteen patients and 95 family 
members were available for testing. All patients were males, four 
of them being sporadic cases, whereas in six families, transmission 
was compatible with X-linkage. Diagnosis of NDI was based on clini­
cal symptoms and the lack of increase of urine osmolality after 
administration of the synthetic vasopressin analogue DDAVP (1-des-
amino-8-D-arginine vasopressin) . Maximal urine osmolalities that 
could be achieved after DDAVP-infusion were 51-198 mosmol/kg (nor­
mal > 805 mosmol/kg). 
DNA analysis 
Venous blood samples (40 ml) from affected and unaffected family 
members were collected in EDTA and stored at -20° С until use. DNA 
isolation was done as previously described (Knoers et al., 1988) : 
20 ml of blood was added to 200 ml sucrose lysis buffer (0.32 M 
sucrose, 5 mM MgCl2, 10 mM Tris-HCl; pH 7.5) and centrifuged for 10 
minutes at 40C and 2,800 g. The supernatant was aspirated and taken 
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Fig. 3.1: Pedigrees of ten families with nephrogenic diabetes insipidus 
(NDI). • Affected males, ©obligatory carriers. 
up in 50 ml lysis buffer. Then the centrifugation was repeated. The 
pellet of white cell nuclei was resuspended in 9 ml of 75 mM NaCl, 
24 mM EDTA (pH 8.0). To this suspension 450 μΐ 10 % sodium dodecyl 
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sulfate (SDS) and 500 μΐ 3 mg/ml proteinase К (Boehringer, Mann­
heim) in 0.2 M Tris-HCl (pH 8.0), 0.2 M EDTA, 0.5 % SDS was added 
and the mixture was incubated at 50oC for 15-18 hours. The diges­
tion mixture was extracted with an equal volume of phenol, followed 
by extraction with phenol:chloroform (1:1) and finally with pure 
chloroform. DNA was precipitated with 0.75 volume of isopropanol 
and 0.01 volume of 5 M NaCl, washed twice with ethanol, dissolved 
in 10 itM Tris-HCl (pH 7.5), 1 mM EDTA and stored at 40C. DNA sam­
ples were digested to completion using the appropriate restriction 
enzyme under conditions recommended by the suppliers. The resulting 
fragments were separated according to size by agarose gel electro­
phoresis (0.9 to 1.5 % agarose gel) and transferred to Gene Screen 
plus filters (NEN research products, Boston) by the Southern blot 
method (Southern, 1975). After the blotting, filters were rinsed 
in 50 mM phosphate buffer and irradiated with ultraviolet light for 
1-2 minutes. DNA probes (200-400 ng) were radiolabelled with 50 ßCi 
32P-dCTP to a specific activity of 2.5xl08 cpm^g using the primer 
elongation method (Feinberg and Vogelstein, 1983). Gene screen plus 
membranes were prehybridized for 4-6 hours at 650C in 10 ml 0.5 M 
sodium phosphate buffer (pH 7.3), containing 7 % SDS, 1 mM EDTA 
with addition of 500 дд sonicated herring sperm DNA. Hybridization 
was performed overnight at 650C in 10 ml prehybridization solution 
to which 250 ßg sonicated herring sperm DNA and denatured probe had 
been added. The filters were washed three times for 5 minutes and 
once for 30 minutes, respectively, in 40 mM sodium phosphate buffer 
(pH 7.3) and 1 % SDS at 650C. 
Autoradiography was carried out at - 70oC using Kodak X-Omat S X-
ray films for 1-3 days with intensifying screens. 
Probes 
Ten X-chromosome specific cloned DNA probes corresponding to the 
loci DXYS1, F9, DXS105, DXS15, DXS52, DXS134 and F8 were used in 
the linkage analysis. As shown in Table 1 each probe detects at 
least two allelic DNA fragments. For probe cpX.67 an Mspl polymor-
phism has been described, which consists of two allelic bands of 
3.7 and 3.4 kb (Hofker et al., 1987). In our family studies the 
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respective Mspl fragments were slightly different, i.e. 
3.2 kb. 
4.1 and 
Table 3.1 
Locus 
DXYS1 
Έ9 
DXS105 
DXS15 
DXS52 
F8 
DXS134 
X-chomosome markers used 
Probe 
pDP34 
pVIII 
рХШ 
[ pV13 
CX55 7 
DX13 
Stl4 
pll4 12 
1 p482 6 
(.pX67 
Re4tnction 
enzyme 
Taqi 
Taql 
Ddel 
BamWll 
EroRI 
Ta4\ 
Bgm 
Taql 
Bell 
Kpnll 
Xbal 
Mspl 
in t h i s 
Allele size 
(kb) 
118 
10 6 
18 
13 
17S 
170 
80 
63 
53 
35 
58 
28 
12 
09 
62 
14 
37 
34 
study 
s Allele Genomic location 
(requencj 
0 56 
0 44 
0 71 
0 29 
0 24 
0 76 
0 94 
006 
0 16 
084 
0 45 
0 55 
complex 
037 
0 63 
0 41 
0S9 
0 70 
озо 
Xql3-q21 
Xq26-q27 
Xq27-q28 
Xq28 
Xq28 
Xq28 
Xq28 
Reference 
Pdge et al 
(1982) 
Connor et al 
(1986) 
Winshipetal 
(1984) 
Ha) et al 
(1986) 
Hofker et al 
(1987) 
Drayna et al 
(1984) 
Oberlé et al 
(1985) 
Gitschicr et al 
(1985) 
Wion et al 
(1986) 
Hofker et al 
(1987) 
Linkage analysis 
Two-point linkage analysis was performed with the LINKAGE program 
(Lathrop and Lalouel, 1984) and lod scores were calculated for 
various values of the recombination fraction. For the mutant NDI 
allele a gene frequency of 1 in 105 and a mutation rate of 5xl0-6 
were assumed (Haldane, 1935). 
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Table 3.2 Relevant phenotypes of individuals studied (expressed in 
kilobase s ize of ША fragments) .nt, not tested 
Kindred Individual Genotypes 
022 I 1 
II I 
II-2 
023 1-1 
1-2 
II 1 
II-2 
II-3 
114 
Ш-1 
III 2 
III-3 
III-4 
024 II-1 
II-2 
II-4 
115 
III-l 
III-2 
025 II-2 
III-l 
III-2 
III-5 
III 7 
026 II-2 
II-4 
II-5 
II-6 
II-7 
118 
11-10 
11-11 
III-l 
Ш-3 
III 5 
III-7 
Ш-8 
III 9 
III-10 
Ш-11 
IV-1 
IV-2 
027 1-2 
II-l 
III-l 
029 H-i 
II-3 
II-4 
II-5 
IIB 
III-2 
1113 
DXYS1 
11 8/10 6 
10 6 
118 
10 6 
11 8/11 8 
nt 
118 
11 8/10 6 
118/10 6 
nt 
nt 
10 6 
118 
118 
118 
118 
118/10 6 
118 
10 6 
118/10 6 
10 6 
10 6 
10 6 
10 6 
10 6 
10 6/10 6 
10 6 
118/10 6 
118 
118 
10 6/10 6 
10 6/10 6 
10 6 
118/10 6 
10 6 
10 6 
10 6 
10 6 
10 6 
10 6 
118 
10 6 
118/10 6 
118/10 6 
118 
118 
10 6 
10 6 
1 1 8 
118/10 6 
10 6 
1 1 8 
F9 
1 8 / 1 3 ' 
1 8 
1 8 
1 3 ' 
18/18 
nt 
1 8 
18/13 
1 8 / 1 3 
1 8 
1 3 
1 3 
1 8 
18" 
1 8 
1 8 
18/13 
1 8 
1 8 
8 0/6 3" 
8 0 
6 3 
8 0 
6 3 
1 3 ' 
1 8 / 1 3 
1 8 
18/18 
1 8 
1 8 
18/13 
18/13 
1 3 
18/18 
1 8 
1 3 
1 3 
1 8 
1 8 
1 8 
1 8 
IB 
1 8 / 1 3 ' 
18/18 
1 8 
I S ­
I S 
1 8 
1 3 
18/13 
1 3 
1 8 
DXS15 
5 8 / 2 8 
5 8 
2 8 
nt 
-
-
-
-
-
-
-
-
-
5 8 
5 8 
2 8 
5 8 / 2 8 
5 8 
2 8 
5 8 / 2 8 
2 8 
2 8 
5 8 
5 8 
2 8 
5 8 / 2 8 
2 8 
5 8 / 2 8 
2 8 
2 8 
5 8 / 2 8 
5 8 / 2 8 
2 8/2 8 
5 8 
2 8 
2 8 
2 8 
2 8 
2 8 
2 8 
5 8 
5 8 
nt 
5 8 0 8 
5 8 
_ 
-
-
-
-
-
-
DXS52 
5 3/4 1 
4 1 
5 3 
3 4 
5 3/3 9 
5 3 
3 9 
3 9/3 4 
5 3/3 4 
3 9 
3 4 
3 4 
5 3 
4 8 
4 8 
4 8 
5 3/4 8 
4 8 
5 3 
4 8 / 3 9 
3 9 
3 9 
4 8 
4 8 
5 3 
4 0 / 3 9 
3 9 
4 0/3 9 
3 4 
3 9 
5 3/4 0 
5 3/4 0 
3 9 
4 0/3 4 
3 9 
5 3 
5 3 
5 3 
5 3 
5 3 
4 0 
4 0 
5 3/4 5 
5 3/5 3 
5 3 
4 5 
4 5 
4 5 
4 5 
4 8 / 3 4 
3 4 
4 8 
F8 
12/0 9" 
0 9 
1 2 
12" 
12/0 9 
nt 
0 9 
12/0 9 
12/0 9 
nt 
nl 
1 2 
0 9 
0 9" 
0 9 
0 9 
12/09 
0 9 
1 2 
6 2/14* 
6 2 
6 2 
1 4 
1 4 
1 4 ' 
14/14 
1 4 
14/1 4 
6 2 
1 4 
14/14 
1 4 / 1 4 
1 4 
6 2/14 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
1 4 
12/0 9" 
12/09 
1 2 
_ 
-
-
-
-
-
-
DXS134 
_ 
-
-
4 1 
3 2/3 2 
3 2 
3 2 
4 1/3 2 
4 1/3 2 
3 2 
4 1 
4 1 
3 2 
_ 
-
-
-
-
-
4 1/32 
3 2 
3 2 
4 1 
4 1 
_ 
_ 
_ 
-
_ 
-
-
-
-
-
-
-
-
-
-
-
-
-
3 2 / 3 2 
4 1/3 2 
4 1 
4 1 
4 1 
nt 
nt 
4 1/3 2 
4 1 
3 2 
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Table 3.2 (continued) 
Kindred 
030 
046 
047 
Individual 
IM 
11-6 
II-7 
III-l 
Ш-2 
ІІЫ 
IV-2 
II-l 
II-2 
II-3 
III-l 
III-2 
III-3 
1-1 
II 1 
II-2 
II-3 
II-4 
II-6 
III-l 
III-2 
III-3 
III 6 
III-7 
Ш-9 
III 11 
III-12 
III 16 
III 17 
Ш-18 
III 19 
III-20 
IV-1 
IV-2 
Genotypes 
DXYS1 
10 6 
10 6/10 6 
10 6 
10 6 
10 6 
10 6/10 6 
10 6 
10 6 
118/118 
118 
118 
118 
11 8 
m 
11 8/10 6 
11 8/11 8 
118/10 6 
11 8/10 6 
11 8/118 
10 6 
118 
118 
10 6 
118 
10 6/10 6 
nt 
118 
118 
118 
11 8 
11 8 
118 
10 6 
10 6 
F9 
18' 
18/13 
18 
18 
13 
18/1 3 
13 
18" 
18/18 
13 
18 
18 
18 
ntc 
-
18/17 
-
18/1 7 
-
18 
-
-
1 7/1 7 
-
-
18 
ni 
17 
nt 
1 8 
ni 
nt 
DXS15 
-
-
-
-
-
-
-
_ 
-
-
-
-
-
-
-
2 8 / 2 8 
2 8 / 2 8 
-
2 8 / 2 8 
-
-
-
-
-
5 8 / 2 8 
-
-
-
-
-
-
-
58 
28 
DXS52 
53 
4 8/4 0 
39 
4 8 
4 0 
4 0/3 9 
4 0 
45 
4 8/4 5 
4 8 
4 8 
4 8 
45 
3 4 
4 8/3 4 
4 8/3 4 
4 8/3 4 
4 8/3 4 
4B/3 4 
34 
34 
4 8 
34 
34 
5 3/4 8 
34 
4 8 
4 8 
4 8 
34 
34 
48 
53 
4 8 
F8 
_ 
-
-
-
-
-
-
0 9 d 
0 9/0 9 
12 
0 9 
0 9 
0 9 
_ d 
-
0 9/0 9 
0 9/0 9 
-
0 9/0 9 
-
-
-
-
-
0 9/0 9 
-
-
-
-
-
-
-
09 
09 
DXS134 
-
-
-
-
-
-
-
32 
4 1/3 2 
4 1 
4 1 
41 
32 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
8
 Taql polymorphism 
bBamHVEcoRl polymorphism 
'Ddel polymorphism 
d
 Öc/I polymorphism 
^KpnVXbal polymorphism 
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3.4. RESULTS 
Each of the 10 NDI families was informative for at least one of the 
seven polymorphic DNA markers employed. Probe Stl4, defining locus 
DXS52, was informative in nine out of ten families and yielded a 
total of 36 scorable méioses. The genotypes of all individuals, 
that are relevant to the analysis, are presented in Table 2. 
Genotypes for DXS105 are not shown as only one family was infor-
mative for this marker. 
Two-point linkage data for NDI and the seven DNA markers are 
summarized in Table 3. 
Table 3.3 Linkage relationships for nephrogenic diabetes insipidus 
(NDI) and marker loci 
Marker 
DXYSl 
F9 
DXSIOS 
DXS15 
DXS52 
F8 
DXS134 
No of 
informative 
families 
8 
8 
1 
5 
9 
5 
5 
Lod scores 
0 (recombination fraction) 
0 00 0 01 
-
-
0 10 
3 02 
10 35 
2 19 
209 
-14 58 
- 7 35 
009 
3 08 
10 33 
2 16 
2 07 
0 05 
-7 19 
2 70 
008 
2 94 
944 
1 98 
1 89 
0 10 
- 4 24 
- 1 14 
006 
2 50 
8 41 
175 
168 
0 20 
- 2 10 
- 0 0 6 
0 02 
180 
6 25 
1 28 
122 
0 30 
- 0 59 
0 29 
0 01 
1 12 
396 
0 78 
0 75 
0 40 
- 0 11 
0 19 
000 
0 47 
163 
0 34 
0 29 
000 
0 31 
0 10 
3 23 
10 35 
2 19 
209 
9b 
0 50 
0 32 
000 
000 
000 
000 
000 
aMaximum likelihood estimation of the lod score 
^Recombination fraction at ζ 
There was no evidence of linkage between NDI and the most proximal 
marker tested DXYSl (pDP34). Lod scores were uniformly negative for 
all values of Θ. Similarly, close linkage was excluded for the 
second most proximal marker tested, F9 (pVIII, pXIII, and pVI.3). 
The maximum combined lod score was 0.29 at θ= 0.30. The θ max be­
tween NDI and DXSIOS (cX55.7) was not significant. Tight linkage 
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was found between the gene coding for NDI and the markers DXS15 
(DX13), DXS52 (Stl4), F8 (pll4.12 and p482.6) and DXS134 (cpX.67). 
These markers are located within band Xq28 and are closely linked 
(Oberlé et al., 1985; Hofker et al., 1987). 
No cross-overs were observed between NDI and each of these four 
markers, giving maximum lod scores of 3.23 (DXS15), 10.35 (DXS52), 
2.19 (F8) , and 2.09 (DXS134) respectively. Thus, our data are not 
instructive as regards the localisation of NDI in relation to the 
Xq28 markers. 
As to the DNA markers in the Xg28 region, we found no cross-overs 
between DXS15 and DXS52. However, in family 023 a recombination 
event was observed between F8 and DXS52 (DXS15 was not informative 
in this family); in family 027 a cross-over separated DXS134 from 
F8 and DXS15 (DXS52 was not informative in this family). 
3.5. DISCUSSION 
We have observed tight linkage and absence of recombination between 
the NDI gene and four marker loci, all of which are known to be lo-
cated at the band Xg28 near the long arm telomere of the X-chromo-
some (Oberlé et al., 1985; Hofker et al., 1987). In contrast, close 
linkage could be excluded for DXYS1 and the F9 marker, both of 
which map further proximal to the Xq and cleary outside the Xq28 
region. 
These results assign the NDI gene to the distal long arm of the X 
chromosome. Moreover, the fact that results for all informative 
families were concordant argues against genetic heterogeneity of 
this disorder and suggests that the disease is due to a single Χ­
Ι inked gene defect. 
The assignment of the NDI gene to Xq28 is consistent with a pre­
vious study that has excluded linkage with the Xg blood group, on 
the distal short arm of the X-chromosome (Bode and Miettinen, 
1970). Close linkage of NDI with Xq28 markers is also corroborated 
by a recent study, which was conducted simultaneously in one large 
family (Kambouris et al., 1988; see also Davies et al., 1987). 
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These results place the NDI gene in the vicinity of the genes for 
haemophilia A (McKusick, 1983), adrenoleukodystrophy (ALD) (Abourg 
et al., 1987, van Oost et al., 1987), Emery Dreifuss muscular 
dystrophy (EMD) (Thomas et al., 1986), the Hunter syndrome 
(Upadhyaya et al., 1986), G-6-PD deficiency and colour blindness 
(see Fig. 2). 
xp-
centromere-
Xq-
22 Ш 
Xg 
DMD 
Ш2. 
] 
] ] ND, XLRP 
ШШ. 
—US 
13 
22 
23 
24 
25 
26 
27 
28 
В 
]PGK 
] G A L A 
] H P R T , ' ' ' 
'à,-*' 
INDI 
ALO 
G-6-P0 
Color blindness 
F VII! 
Fig. 3.2: Map of the X chrcmoscme indicating the localization of the 
NDI gene and various other genes. К Ж Fhosphoglycerate kinase, GAIA 
α-galactosidase, HFRT hypoxanthineguanine phosphoribosyltransferase. 
The precise orientation of the NDI gene relative to the afore­
mentioned gene loci remains to be elucidated. To our knowledge, a 
combination of any of these disorders with NDI, which might point 
to a deletion spanning two or more loci, has not been reported to 
date. 
As to the relative order of DNA markers in the Xq28 band, previous 
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reports have been controversial: Drayna and White (1985), employing 
multifactor analysis, determined the most likely order in this re­
gion as centromere-(DXS52, DXS15)-F8-telomere. The same order was 
suggested by Mulligan et al. (1987). They identified a recombina­
tion between DXS52 and F8 in a family with the fragile X syndrome. 
Others proposed the order F8-DXS15-DXS52, based on phase-known 
(Carpenter et al., 1987; Connor et al., 1987; see also Davies et 
al., 1987), and phase-unknown (Vidaud et al., 1987; Bhattacharya 
et al., 1987; see also Davies et al., 1987) recombinations or soma­
tic cell hybrids (Tantravahi et al., 1986). Owing to the scarcity 
of recombination in our families, we could not decide between these 
two possibilities. 
In general, subtelomeric chromosomal regions are characterized by a 
high incidence of cross-overs, which means that compared to the 
physical map, the genetic map of these segments appears to be en­
larged. Therefore, the observed lack of recombination between NDI 
and four Xq28 markers suggests that their physical distance is very 
small. This offers promise for physical mapping and eventually, for 
the isolation of the NDI gene. Further studies will concentrate on 
the ordering of genes in this region, employing other genetic mar­
kers such as the colour blindness genes as well as long-range res­
triction mapping (Carle et al., 1986). 
The closely linked DNA markers, that have been identified in this 
study, should be a valuable tool for reliable carrier detection and 
prenatal diagnosis. Early detection of NDI is important because, if 
not treated, it frequently leads to brain damage and severe mental 
retardation. 
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4.1 ABSTRACT 
The gene for X-linked nephrogenic diabetes insipidus (NDI), a dis-
order which, if untreated, causes severe dehydration, mental retar-
dation, and possibly death in affected males, has been mapped 
recently to the Xq28 band through demonstration of linkage to the 
DXS52 locus and other DNA markers (N. Knoers et al., 1987, Cyto-
genet.Cell genet. 46:640; M.Kambouris et al., 1987, Cytogenet.Cell 
genet. 46:636). Linkage studies in eleven families with NDI have 
enabled us to map the NDI gene between closely linked flanking 
markers in the Xq28 region and to obtain the following gene order: 
centromere-F9-DXS98-F8/CBD,CBP-DXS52/NDI-DXS134-telomere. 
These results have implications for presymptomatic and prenatal 
diagnosis of NDI and should also improve the prospects for iden-
tifying the fundamental gene defect underlying the disorder. 
4.2 INTRODUCTION 
The locus for X-linked Nephrogenic Diabetes Insipidus (NDI) has 
been assigned to the distal long arm of the human X chromosome, by 
demonstrating tight linkage to the DNA-marker loci DXS52 (probe 
Stl4) (Knoers et al., 1988a), DXS15 (probe DX13), F8 (probes 144.12 
and 486.2) and DXS134 (probe cpX67) (Knoers et al., 1988b; Kam-
bouris et al., 1988), all of which are located within band Xq28 
(Oberlé et al., 1985; Hofker et al ., 1987). However, until now, 
the precise location of the disease locus could not be determined, 
because of the absence of recombination between the NDI gene and 
any of the aforementioned restriction fragment length polymorphism 
(RFLP) markers. 
In order to define the position of the NDI locus more precisely and 
to generate a genetic map of the Xq28 region, we have performed 
multipoint linkage analyses in eleven Dutch families employing six 
DNA markers from the distal long arm of the X chromosome. The 
results of these studies are reported in the present communication. 
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4.3 MATERIALS AND METHODS 
Subjects 
Eleven families with NDI from the Netherlands, comprising 20 affec-
ted males, were included in the study. Ten of these families have 
been described previously (Knoers et al., 1988b). Diagnosis of NDI 
was confirmed by the lack of increase of urine osmolality after 
infusion of the synthetic vasopressin analogue DDAVP (l-desamino-8-
D-arginine-vasopressin). Maximal urine osmolalities that could be 
achieved after DDAVP administration were 51-198 mosm/kg (normal 
>805 mosm/kg) . 
DNA analysis 
The methods used in DNA analysis have been described previously 
(Knoers et al., 1988a, 1988b). Briefly, DNA was extracted from 
blood lymphocytes and digested to completion with the appropriate 
restriction enzyme under conditions recommended by the suppliers. 
The restriction fragments were separated electrophoretically and 
transferred to GENE SCREEN PIUS filters (NEN research products, 
Boston) and [32 P]-labeled probes were hybridized to the blots. 
Probes 
Six cloned ENA probes corresponding to the loci F9, DXS98, DXS134, 
DXS52, CBD/CBP, and F8 (Table 1) were used in the linkage analysis. 
Two other markers that were tested, DXS15 (probe DX13) and DXS33 
(probe MN12), were not treated as separate loci in the analysis 
because neither of the two showed recombination with NDI and the 
DXS52 marker (probe Stl4). This is in keeping with recent evidence, 
obtained by long-range physical mapping techniques, that DXS15, 
DXS52, and DXS33 are physically very close (Patterson et al., 
1987) . 
Linkage analysis 
Three-point linkage analysis was performed assuming X-linked re-
cessive inheritance, employing the ILINK programme of the LINKAGE 
package (Lathrop and Lalouel., 1984), which was kindly provided 
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by Dr. J. Ott (Columbia University, New York). The frequency of 
the mutant NDI allele in females was taken as 1 in 10 5 and a 
mutation rate of 5x10 _ б was assumed. For linkage analysis, bio­
chemical abnormalities in females were not taken into account. 
Table 4.1 X-Chrcmoscme markers used in this study 
Locus 
F9 
DXS98 
F8 
DXS52 
DXS134 
CBD.CBP 
Probe 
pVIII 
pXIII 
р І З 
4D8 
p l l 4 12 
p482 6 
St l4 
cpX67 
hs7 
Restriction enzyme 
Taql 
Ddei 
BamHl/EcoRl 
Mspl 
Bea 
Kpnì/Xbal 
Taql 
Mspl 
Sstl 
Allele size 
(kb) 
1 8 
1 3 
1 75 
170 
8 0 
6 3 
25 
7 8 
1 2 
0 9 
6 2 
1 4 
3 7 
3 4 
18 + 7 5 
18 
7 5 
Allele frequency Genonuc location 
0 7 П 
0 29 
0 24 
0 76 
0 94 
0 0 6 
0 82 
0 18 
0 3 7 
0 6 3 
0 41 
0 5 9 
сотріеж 
0 70 
0Э0 
7 
Xq26-q27 
Xq26-qter 
Xq28 
Xq28 
Xq28 
Xq22-q28 
Ref 
(5) 
(29) 
(11) 
(Э) 
(10) 
(30) 
(20) 
(12) 
(19) 
4.4 RESULTS AND DISCUSSION 
Table 2 presents the best-supported order and the relative like­
lihood of alternative orders of all possible three-locus orders of 
six loci (five DNA markers and the disease locus). The F9 marker is 
not included in the table because it maps clearly outside the Xq28 
region. This was confirmed by three-point analyses indicating that 
F9 is located proximal to the other six loci (odds > 100:1, data 
not shown). 
Orders with a posterior probability of less than 0.01 were taken as 
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Table 4.2 Best-supported order of loci and relative likelihoods for 
t h e a l t e r n a t i v e o r d e r s 
DXS98, F8, DXS134, CED, 
Best Bupported order of loci 
(a, b, c) 
NDI-DXS52-F8 
DXS134-NDI-F8 
DXS134-NDI-DXS52 
CBD,CBP-NDI-DXS52 
NDI-CBD,CBP-F8 
CBD,CBP-NDI-DXS134 
DXS98-NDI-DXS52 
DXS9e-NDI-F8 
DXS98-NDI DXS134 
DXS98-NDI-CBD,CBP 
DXS134-DXS52-F8 
CBD,CBP-DXS52-DXS134 
DXS52-CBD,CBP-F8 
DXS98-DXS52-F8 
DXS98-DXS52-DXS134 
DXS98-DXS52-CBD,CBP 
F8-CBD,CBP-DXS134 
DXS134-CBD,CBP-DXS9e 
of a l l p o s s i b l e t h r e e - l o c u s o r d e r s 
СВР, DXS52, and t h e Ю І 
Keepective % recombination 
between adjacent loci 
0 001-0 058 
0 001-0 092 
0 046-0 001 
0 015-0 001 
0 021-0 001 
0 030-0 021 
0 115-0 001 
0 001-0 071 
0 001-0 101 
0 064-0 039 
0 025-0 026 
0 001-0 046 
0 001-0 023 
0 129-0 062 
0 420-0 580 
0 115-0 001 
0 001-0112 
0 044-0 108 
gene. 
involving 
Relative likelihoods of alternative 
b-a-c 
1 
9 7 X 10"1 
4 0 X IO-1 
1 6 X IO"2 
1 0 X IO"2 
6 3 X 10"1 
BOX 10"J 
1 
9 6 X IO"' 
6 4 X 10 ' 
6 2 X IO"1 
1 
1 
3 0 X 10"' 
1 9 X 10" ! 
1 9 X 1 0 " 
9 8 X IO"' 
1 3 X IO"' 
orders 
a c-b 
6 3 X IO"1 
3 1 X IO"' 
1 
1 
7 9 X 1 0 - ' 
8 1 X IO"' 
1 
1 9 X IO"' 
4 9 X IO"' 
4 0 X IO"' 
5 2 X IO"2 
5 0 X 10 5 
7 7 X IO"1 
1 8 X 10 ' 
1 5 X IO"1 
7 9 X 1 0 ' 
4 7 X IO"2 
3 1 X IO"2 
rejected. Comparison of all possible of seven locus orders (inclu­
ding F9) indicated that all except two, given below ,encompassed 
at least one rejected three-locus order: 
(1) F9 - DXS98 - F8/ CBD,CBP - DXS52/ NDI - DXS134 
(2) F9 - DXS98 - DXS134 - DXS52/NDI - F8/CBD,CBP. 
Analysis of individual cross-over events strongly favored possi­
bility 1. Consistently, the gene order F9 - DXS98 - F8/CBD,CBP-
DXS52/NDI -DXS134 requires the least number of recombinants to 
explain segregation patterns observed, as exemplified in Fig.l. 
This map is in perfect agreement with the consensus gene order put 
forward during the most recent Human Gene Mapping conference (HGM9, 
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Davies et al., 1987): Xcen - F9 - DXS105 - DXS98 
DXS52 - DXS15 - DXS134 - qter. 
F8 -DXS33-
m 
Ό 
ί^ϊ 
α 
ο 
A i 
e ι 
h ι 
2 ; 
Ί 
Α 
e 
h 
1 
f 
a 
e 
H 
1 
F 
Fig. 4.1; Pedigree of a family with X-linked nephrogenic diabetes in­
sipidus using five polymorphic Ш А markers on Xq (DXS98/p4D8:A,a; 
F8/pl44.12: E,e; CBDjCBP/phsV: H,h;DXS52/pStl4:l,2; DX5134/ cpX67: F,f) 
• affected males;{·) obligatory carrier, 
Taken together, the results indicate that the NDI gene maps in the 
close vicinity of the markers DXS52, DXS33 and DXS15. Moreover, 
these analyses provide us with closely linked flanking markers for 
the NDI gene: F8 as well as CBD,CBP on one and DXS134 on the other 
side of the disease locus. This finding should greatly increase the 
reliability of both carrier detection and early (prenatal) diagno­
sis of NDI. Early detection is a prerequisite for early treatment 
of the disease, which can prevent brain damage and severe mental 
retardation. 
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In addition, the refined genetic mapping achieved in this study 
should improve the prospects for cloning the NDI gene, because, 
compared to is physical length, the subtelomeric Xq region is 
characterized by a high rate of recombination. Given the tight 
linkage between NDI and several Xq28 markers, this implies that the 
corresponding physical distances may be very small. This, as well 
as the available unique collection of NDI patients, offers promise 
for the detection of structural aberrations, such as small dele­
tions, employing Southern blotting and pulsed-field gel electropho­
resis with DNA probes from the F8-DXS134 interval. 
Submicroscopic deletions have been detected in a variety of X-
linked disorders (Wieringa et al., 1985; Gal et al., 1985; Cremers 
et al., 1987) and have paved the way for the molecular isolation of 
several genes (Monaco et al., 1986; Royer-Pokora et al.,1986; Page 
et al., 1987). 
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5.1. ABSTRACT 
Fibrinolytic responses to infusion of l-desamino-8-D-arginine-
vasopressin (DDAVP) were assessed in 6 males with congenital 
Nephrogenic Diabetes Insipidus (NDI), б carriers of the NDI gene 
and 6 normal control subjects. Tissue-type plasminogen activator 
(t-PA) activity and antigen increased significantly in normal sub­
jects, while plasminogen activator inhibitor (PAI) activity de­
creased. None of these changes were observed in patients with NDI. 
In 2 female carriers normal fibrinolytic responses were seen, while 
in the other carriers responses were delayed. These findings are 
consistent with the concept of a general V2-receptor defect in con­
genital NDI. DDAVP tests are of limited use in NDI carrier detec­
tion. 
5.2. INTRODUCTION 
The neurohypophyseal hormone arginine vasopressin (AVP) exerts its 
effects through stimulation of at least two pharmacologically dis­
tinct classes of receptors: The pressor response of this hormone 
and other actions, such as glycogenolysis and platelet aggregation, 
are mediated via vascular (V^) receptors, while the antidiuretic 
effect is mediated via renal tubular (V2) receptors. V2 vasopressin 
receptors are linked to a membrane adenylate cyclase, whereas bin­
ding of vasopressin to V^ receptors has been shown to stimulate 
phosphatidylinositol breakdown and Ca 2 + mobilization. Apart from 
differences in functional properties, V^ and V2 receptors can be 
distinguished by their vasopressin analogue recognition pattern [1-
2]. 
l-desamino-8-D-arginine vasopressin (DDAVP or Desmopressin) is a 
synthetic derivative of the native hormone which has potent anti­
diuretic V2-activity but, unlike vasopressin and other analogues, 
is virtually free of stimulating effects on blood pressure [3]. 
These differences are the result of molecular modification of 
vasopressin involving deamination of hemicysteine at position 1 
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which results in a more prolonged duration of antidiuretic action, 
and substitution of the D-isomer of arginine for L-arginine at 
position 8 which results in a diminished pressor activity. In con­
trast, DDAVP exerts a considerable vasodilatory action, manifested 
by flushing, a fall in diastolic blood pressure and a rise in pulse 
rate [4]. 
Other extrarenal effects of DDAVP have been described recently: The 
drug provokes a marked, transient, release of factor VIII coagulant 
activity (FVIII:C) and von Willebrand factor antigen (vWF:Ag) from 
endothelial storage sites [5]. Because of this property DDAVP is 
well established in the treatment of mild and moderate hemophilia A 
and type I von Willebrand's disease [6-9]. 
In addition, DDAVP causes a significant dose-dependent increase in 
fibrinolytic activity and this has been attributed to a rapid re­
lease of extrinsic (tissue-type) plasminogen activator (t-PA) into 
the circulation [10]. The mechanisms by which desmopressin causes 
vasodilatation and increases in FVIII components and t-PA levels 
are still incompletely understood. 
Patients with X-linked Nephrogenic Diabetes Insipidus (NDI) are re­
sistant to the antidiuretic action of vasopressin and DDAVP [11], 
due to a defect either in the renal V2-receptor itself or in the 
process beyond the intracellular formation of cyclic-AMP [12]. 
Kobrinsky et al. [13] have demonstrated absence of FVIII:С and 
vWF:Ag responses to DDAVP in 2 NDI patients. From this observation, 
they concluded that the action of DDAVP on haemostasis is mediated 
through stimulation of extrarenal V2-receptors. Recently, this as­
sumption was supported by the investigation of Bichet et al.[14], 
showing absence not only of FVIII release, but also of haemodynamic 
effects in 7 NDI patients after administration of desmopressin. 
They speculated that the interaction of desmopressin with these 
extrarenal V2-receptors could be responsible for both the vaso­
dilatory effects and the increase in FVIII components. t-PA levels 
were not quantified in these studies. These findings have prompted 
us to evaluate fibrinolytic parameters, such as t-PA antigen, t-PA 
activity and the recently discovered plasminogen activator inhibi­
tor (PAI) [15] in NDI patients and healthy controls following infu-
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sion of DDAVP. In addition, we have measured DDAVP-induced fibrino-
lytic responses in NDI carrier females. 
5.3. MATERIAL AND METHODS 
Subjects 
Our study included 6 patients with X-linked recessive NDI, 6 female 
NDI carriers and 6 healthy control individuals. Approval of the Me-
dical Ethical Commission of the hospital was obtained for this in-
vestigation. In the patients, aged 8, 15, 16, 22, 25 and 26 years, 
respectively, diagnosis of NDI was based on clinical symptoms and 
the lack of increase of urine osmolality after administration of 
DDAVP. Maximal urine osmolalities that could be achieved after 
DDAVP infusion were 51-198 mosm/kg (normal >805 mosm/kg). The pedi-
grees of the 6 patients have been described elsewhere [16]. All 
patients discontinued hydrochlorothiazide medication 24 hours 
before the study. 
Heterozygote female carriers (43-54 years old) were identified by 
DNA linkage analysis with various DNA markers known to be closely 
linked to the NDI gene on the subtelomeric region of the long arm 
of the X chromosome [16,17]. 
The control group consisted of 6 healthy volunteers, 2 women and 4 
men (24-28 years old), who had agreed to participate in the experi-
ment and were fully aware of the purpose of the investigation. The 
women were not using oral contraceptives, which are known to affect 
t-PA levels [18]. 
DDAVP administration 
Throughout the experiment DDAVP tests were always performed in the 
morning between 9.00 and 11.00 a.m. to avoid the influence of the 
normal daily fluctuation of fibrinolytic activity [19]. 
The DDAVP (Minrin R) was supplied by Ferring Pharmaceuticals AB 
(Malmö, Sweden). A dose corresponding to 0.3 дд DDAVP/kg body 
weight was diluted in 100 ml saline and was injected slowly over a 
period of 10 min into a cubital vein of the recumbant subject, 1 
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hour after his confinement to bed. A 4.5 ml blood sample was col­
lected from the indwelling venipuncture 10 min before, immediately 
before and 10, 20, 30, 60 min after the start of the infusion. 
Systolic and diastolic blood pressure and heart rate were monitored 
at 3-min intervals during and 15 min after the study. 
Blood samples 
Blood samples were transferred into plastic tubes, containing 0.5 
ml 3.8% sodium citrate, and cooled immediately on melting ice. 
Platelet-poor plasma, obtained by centrifugation at 4° С for 10 min 
at 3,000g, was quickly frozen in aliquots of 1.5 ml and stored at 
-70° С until assays were performed. 
Assay methods 
t-PA antigen was quantified by an enzyme immunoassay [20]. t-PA-
activity was measured in an amidolytic assay system exactly as des­
cribed by Verheyen et al. [21], using a chromogenic plasmin sub­
strate, H-D-Val-Leu-Lys-p-nitroanilide (S2251 from Kabi Vitrum, 
Stockholm, Sweden), human lys-plasminogen and soluble fibrin frag­
ments prepared by digestion of human fibrinogen (grade L, Kabi 
Vitrum, Stockholm, Sweden) with cyanogen bromide. This assay is 
based on t-PA mediated conversion of plasminogen to plasmin , which 
in turn cleaves an oligopeptide-nitro-anilidine substrate. The p-
nitroaniline released is measured spectrophotometrically. PA-
inhibitor was determined by titration of 1:20 fold diluted plasma 
with stepwise increasing amounts of purified t-PA [21]. 
Statistical methods 
Separate for each time point the method analysis of variance was 
applied, based on logarithmic transformed data, and a mutual com­
parison was done using the method of Tukey [22]. 
5.4. RESULTS 
The fibrinolytic responses to DDAVP obtained in control subjects, 
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Fig.5.1 : t-PA activity response to DDAVP infusion in normal 
controls ( ) and NDI patients ( ). Values at 0 min are 
expressed as 100%. Bars indicate 1 + SE. 
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Fig·5.2 : t-PA antigen response to DDAVP infusion in normal 
controls ( ) and NDI patients ( ). Values at 0 min are 
expressed as 100%. Bars indicate 1 + SE. 
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Fig.5.3 : t-PA inhibitor activity response to DDAVP infusion in 
normal controls ( ) and NDI patients ( ). Values at 0 min 
are expressed as 100%. Bars indicate 1 + SE. 
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Fig.5.4 : t-PA activity response to DDAVP infusion in 6 female NDI 
carriers. Values at 0 min are expressed as 100%. Normal range (as 
derived fron Fig.l) is indicated. 
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NDI patients and carrier females are shown in Fig.l for t-PA 
activity, in Fig.2 for t-PA antigen and in Fig.3 for t-PA inhibitor 
(PAI) activity. Results are expressed as percentages of baseline 
values. In normal subjects the infusion of DDAVP produced a 15-fold 
rise (p < 0.05) in t-PA activity and a 2-fold rise in t-PA antigen 
(p < 0.05) within 10 min, while PAI activity decreased slightly 
within 20 min. In contrast, none of the patients with congenital 
NDI showed any significant change in t-PA activity, t-PA antigen, 
and PAI values. The fibrinolytic responses in the 6 female NDI car-
riers were rather diverse as exemplified in Fig.4 for t-PA activi-
ty. After 10 min, 2 carriers showed a normal increase in t-PA ac-
tivity, while the other 4 demonstrated blunted responses, with the 
mean response for all carriers amounting to 40 % of mean control 
values. After 20 min the majority of carriers showed t-PA levels in 
the range of normal conrols. 
Comparison between patients and normal subjects indicated that t-PA 
activity responses in patients with NDI were significantly (p<0.05) 
different from those in normal subjects at each sampling time. 10 
min after DDAVP injection t-PA antigen values in NDI patients were 
significantly (p<0.05) different from those in normal control indi-
viduals. 
PAI levels did not significantly differ between the two groups at 
any sampling time. 
DDAVP infusion was followed by a decrease in diastolic blood pres-
sure and a significant rise in pulse rate in all normal individuals 
but in none of the NDI patients (data not shown). 
Flushing was observed in some, but not in all normal subjects, but 
was absent in all NDI patients. No other side effects to the drug 
were experienced. Haemodynamic responses in female carriers varied 
widely (data not shown). 
5.5 DISCUSSION 
Nephrogenic diabetes insipidus is an X-linked recessive disease, 
characterized by polyuria, polydipsia, severe dehydration, fever, 
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anorexia and failure to thrive. These clinical features are attri-
buted to unresponsiveness of the distal renal tubule to the V2 
receptor-mediated antidiuretic effect of endogenous and exogenous 
vasopressin. V^ ^ receptors seem to be intact in NDI patients, since 
they have normal pressor responses to vasopressin [23]. 
The present study shows that, in contrast to normal individuals, 
patients with NDI do not show increased fibrinolytic activity 
after administration of the specific V2 agonist DDAVP. This lack 
in response is due to absence of t-PA release from the vascular 
endothelium and cannot be attributed to a high level of fast-acting 
t-PA inhibitor (PAI), since in the majority of NDI patients, t-PA 
inhibitory capacities in plasma were found to be in the normal 
range. 
Our results indicate that the DDAVP-induced increases in t-PA le-
vels after DDAVP infusion, as well as the previously described 
elevation of FVIII components and the vasodilatatory effects, are 
mediated through stimulation of extrarenal V2 receptors. 
At present, the exact location of these extrarenal DDAVP-responsive 
V2 receptors remains to be elucidated. There is little evidence to 
suggest that these receptors are situated on the endothelium itself 
and are stimulated directly by DDAVP. For instance, no significant 
release of FVIII:C and vWF:Ag is seen after addition of DDAVP to 
cultured endothelial cells [24,25] or direct perfusion of isolated 
human vessels [26]. On the other hand, it has been suggested that 
these receptors may be located in the central nervous system. Cash 
et al. [27] hypothesized that vasopressin-like molecules may be 
humoral messengers acting on a cephalic centre, which may in turn 
release a second messenger that stimulates the endothelial cells 
indirectly. However, this putative second messenger has not been 
identified in bovine pituitary and hypothalamic extracts [28]. In 
addition, patients with hypopituitarism resulting from çurgical 
adenohypophysectomy respond normally to desmopressin [29,30]. In a 
study with anephric patients, it was demonstrated that a functio-
ning kidney is not required for the effect of DDAVP on the fibri-
nolytic activity of the blood [31]. 
Notwithstanding our present ignorance about the exact cellular site 
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of the DDAVP receptors, the observation that in NDI patients the 
V2 agonist DDAVP does not affect diuresis, or induce haemodynamic 
[14], haemostatic [13,14] or fibrinolytic (this study) changes 
supports the concept of a general V2 receptor defect in this 
disease. 
In female carriers, Kobrinsky et al. [13] have found up to 50 % of 
the increase in FVIII:C and vWF:Ag after administration of DDAVP in 
3 NDI carriers (as expected assuming random X inactivation in fe-
male individuals) and suggested that DDAVP may be of help in iden-
tifying NDI carriers in families at risk. In our study, we also 
found a diminished fibrinolytic response in NDI carriers 10 min 
after DDAVP administration. However, after 20 min the majority of 
carriers demonstrated responses similar to normal controls. This 
delayed increase in plasma t-PA levels is most likely due to a 
reduced amount of functional V2 receptors in those NDI carriers as 
there is no evidence that t-PA synthesis or storage in NDI is dif-
ferent from normal. In general, our results are in agreement with 
those of Kobrinsky et al. However, it is clear that in 2 carriers 
normal responses were obtained. This means that in some cases 
identification of carriers by means of DDAVP infusion might be 
misleading. 
Recently, the localization of the gene responsible for NDI has 
provided us with closely linked markers, which have been shown to 
be of use for reliable identification of carriers [16,17]. 
In summary, we have investigated the fibrinolytic responses to 
DDAVP in patients with X-linked recessive Nephrogenic Diabetes 
Insipidus, heterozygote female carriers of the NDI gene and normal 
control individuals. We observed no fibrinolytic responses to DDAVP 
in NDI patients and normal responses in some carriers. Therefore, 
DDAVP tests appear to be of limited use for the detection of female 
NDI carriers. Our results suggest that the fibrinolytic effects 
exerted by DDAVP, in addition to the previously described haemo-
dynamic and coagulation responses, depend on extrarenal V2 recep-
tor activation. 
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6.1 ABSTRACT 
In congenital Nephrogenic diabetes insipidus (NDI) blunted respon-
ses of plasma factor VIII, von Willebrand factor, and plasminogen 
activator to the synthetic V2 analogue l-desamino-8-D-arginine 
vasopressin (DDAVP) have been reported. In addition, vasodilatory 
responses to DDAVP appear to be absent in NDI. We describe a boy, 
who presented shortly after birth with the typical features of NDI, 
but who showed normal coagulation, fibrinolytic and vasodilatory 
responses to DDAVP. We conclude that in this patient the defect is 
confined to the kidney, while in other NDI patients there may be a 
general V2 receptor abnormality. These findings point to hetero-
geneity in NDI. 
Key words: Nephrogenic Diabetes Insipidus - Heterogeneity 
Abbreviations: NDI= nephrogenic diabetes insipidus; c-AMP = cyclic 
adenosine monophosphate; DDAVP = l-desainino-8-D-arginine vaso-
pressin; vWF:Ag = von Willebrand factor antigen; FVIII:C = factor 
VIII coagulant activity; t-PA = tissue-type plasminogen activator; 
DNA = deoxyribonucleic acid; RFPL = restriction fragment length 
polymorphism 
6.2 INTRODUCTION 
Nephrogenic diabetes insipidus (NDI) is a rare congenital disease, 
in which the kidneys are resistant to the antidiuretic action of 
both endogenous and exogenous vasopressin. As a consequence the 
kidney loses its ability to concentrate urine. The disease is 
transmitted as an X-linked recessive trait [3,31] although other 
modes of inheritance have been described [25]. Recent studies have 
mapped the NDI gene to the distal long arm of the human X chromo-
some on the basis of linkage analysis of affected kindreds with 
restriction fragment length polymorphisms (RFLPs) [14,15]. 
The main clinical features of the disease are dehydration in infan-
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су and early childhood before the autonomy of drinking is esta­
blished and polydipsia in later life. Some patients with NDI are 
mentally retarded probably due to severe dehydration and hyper-
el ectrolytemia early in infancy. 
The molecular pathogenesis of the disease is unknown. The antidiu­
retic effect of vasopressin and its synthetic analogue l-desamino-
8-D-arginine vasopressin (DDAVP) is mediated through c-AMP depen­
dent receptors (so-called V2 receptors) in the distal renal tubule. 
Theoretically, the defect could be located i η the V2 receptor it­
self, somewhere between the receptor and the production of c-AMP, 
or in the process beyond the intracellular formation of c-AMP. 
In addition to mediating antidiuresis, DDAVP induces several extra­
renal effects. It provokes a marked transient release of von Wille-
brand factor antigen (vWF:Ag), factor VIII coagulant activity 
(FVIII: C) and plasminogen activator [7] from endothelial storage 
sites and exerts a vasodilatory action manifested by facial flus­
hing, a fall in diastolic blood pressure and a rise in pulse rate 
[6]. Recent studies have demonstrated that patients with NDI do not 
show these changes in haemodynamic [2], coagulation [2,17] and fi­
brinolytic [16] parameters after administration of DDAVP. Contrast­
ing with these observations, the study is presented of a 4 year old 
boy with severe NDI, who had normal vWF:Ag-, plasminogen-activator-
and vasodilatory responses to DDAVP. These contrasting observations 
argue for heterogeneity in NDI. 
6.3 CASE RETORT 
The patient J.В., a Caucasian male infant, was b o m after a full-
term pregnancy by ceasarian section, carried out because of lack of 
progress of labour. He was the second child of unrelated parents. 
Birth weight was 3590 g. His postnatal course was complicated by 
hyperbilirubinemia, for which he received phototherapy for two 
days. He was discharged on the 10th day of life, having regained 
his birth weight. At the age of 2 months he was readmitted to the 
hospital because of failure to gain weight normally, constipation, 
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dehydration and fever, which had persisted since the age of two 
weeks. On admission a dystrophic, slightly dehydrated child was 
seen with weight just 600 g above the birth weight. Serum sodium 
was 170 mmol/1, chloride 130 mmol/l and daily urine output ranged 
from 1000 to 1400 ml with very low urine osmolality (<70 mosmol/ 
kg). Proteinuria, glycosuria and hyperaminoaciduria were absent. 
Persistance of a constantly low, fixed urinary osmolality together 
with continuing hypematremia suggested the diagnosis of NDI. The 
diagnosis was confirmed by the lack of increase of urinary osmola­
lity after administration of DDAVP. Additional measurement of uri­
nary cAMP levels before and after DDAVP (20 дд, intranasally) admi­
nistration revealed that the average increment was from 5.87 to 
7.02 ηιαοΐ/μταοί creatinine, that is, only 119 % rise from baseline 
value. 
There was no history of diabetes insipidus in the family. DNA ana­
lysis with the probe Stl4, that defines the DNA marker DXS52, which 
has previously been shown to be closely linked to the NDI gene 
[14], showed that J.B. had inherited the same Stl4 allele from his 
mother as his healthy brother. This Stl4 allele came from the ma­
ternal grandfather. 
After informed consent had been obtained from both parents, a DDAVP 
infusion test was performed to evaluate extrarenal responses to 
DDAVP. 
6.4 METHODS 
48 hours before the study the patient discontinued all medication. 
Food and water were not restricted either before or during the 
test. After one hour recumbancy, a dose of 0.3 дд DDAVP ( Minrin, 
Ferring Pharmaceuticals, Malmö, Sweden)/kg body weight was dilu-
ted in 100 ml saline and was injected slowly over a period of 10 
min into a cubital vein. 
Systolic and diastolic blood pressure and heart rate were monitored 
at 3-min intervals during the first 25 min and at 10 min intervals 
thereafter. A 4.5 ml blood sample was collected from the indwelling 
148 
venipuncture 10 min before, immediately before and 10, 20, 30, and 
60 min after the start of the infusion. Blood samples were trans­
ferred into plastic tubes containing 0.5 ml 3.8% sodium citrate, 
and cooled immediately on melting ice. Platelet poor plasma, ob­
tained by centrifugation at 4 0C for 10 min at 3,000g, was quickly 
frozen in aliquots of 1.5 ml and stored at -70 oC until assays were 
performed. vWF:Ag was measured by an enzyme-linked immunosorbent 
assay from Boehringer, Mannheim, Germany. Tissue-type plasminogen 
activator (t-PA) antigen was quantified by an enzyme immunoasssay 
according to Rijken et al. [24]. t-PA activity was measured by an 
amidolytic assay system as described by Verheyen et al.[30]. 
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Fig. 6.1 : vWF:Ag response to DDSVP in patient J.B. ( * * ) , normal 
control subjects (· ·) and б other NDI patients ( A • ). 
Results at 0 min are expressed as 100 %. Bars indicate 1 ± S.E. 
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All data were compared with those obtained in 6 other NDI patients 
(aged 8-24 years) and in б control subjects (aged 24-28 years). 
The significance of changes during the study were assessed by ana­
lysis of variance. 
6.5 RESULTS 
The responses t o DDAVP obtained i n J . В . , 6 o t h e r NDI p a t i e n t s and 
in 6 normal c o n t r o l s a r e depicted in F i g . l for vWF:Ag, in Fig.2 for 
t-PA a c t i v i t y and in Fig .3 for t-PA ant igen. I n normal sub ject s ad­
m i n i s t r a t i o n of DDAVP caused a 1.5- t o 2-fold r i s e in vWF:Ag within 
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Fig. 6.2; t-PA act iv i ty response t o DDAVP in pat ient J .B. (*— 
mal control subjects ( · · ) and 6 other NDI pat ients ( • — 
Results a t 0 min are expressed as 100 %. Bars indicate 1 ± S.E. 
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30 min, a 15-fold rise in t-PA activity within 10 min and a two­
fold rise in t-PA antigen within 10 min. All changes were signifi­
cant (p<0.05). Similar responses were seen in patient J.B. vWF:Ag 
increased by 200 % within 20 min, t-PA activity by 1309% within 10 
min and t-PA antigen by 219% within 10 min. In contrast, none of 
the other 6 patients showed any significant change in vWF:Ag le­
vels, t-PA activity and t-PA antigen values. 
DDAVP infusion was followed by a significant decrease in diastolic 
blood pressure (10-15%) and a significant rise in pulse rate (15-
20%) in all normal individuals. Similar results were obtained in 
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J.B., while no haemodynamic changes were seen in any of the other 
NDI patients. Flushing was observed in some, but not in all, normal 
subjects, and in patient J.В., but was absent in the 6 other NDI 
patients. 
6.6 DISCUSSION 
The antidiuretic effect of vasopressin and its synthetic analogue 
DDAVP is mediated by renal c-AMP dependent vasopressin receptors. 
These receptors have been classified as V2 receptors to distinguish 
them from the calcium dependent V^ receptors, which mediate the 
pressor response to vasopressin [11,12]. In addition to mediating 
antidiuresis, an apparant V2-mediated action of DDAVP causes re­
lease of vWF:Ag, FVIII:C, and plasminogen activator [7] from endo­
thelial storage sites and exerts a vasodilatory action in normal 
individuals [6]. Recent studies have shown that NDI patients do not 
show these extrarenal responses to DDAVP [2,16,17]. 
Based on these observations it was suggested that there may be a 
general V2 receptor defect in this disease. The patient presented 
in this report is of particular interest because he had normal 
vWF:Ag-, plasminogen activator- and vasodilatory responses to DDAVP 
administration. In contrast to the blunted responses observed in 
our other NDI patients, the extent of the response in J.B. was si­
milar to those in the 6 normal subjects studied. Therefore, he does 
not have a generalized V2 receptor abnormality. 
There is no doubt that he has vasopressin-resistant diabetes insi­
pidus. The clinical symptoms, the fixed low urinary osmolality and 
the impaired antidiuretic response to DDAVP in the cibsence of other 
renal dysfunctions are all in keeping with the diagnosis. 
Similar patients have been reported. Brenner et al. [5] described 4 
patients, who showed normal plasma factor VIII and vWF responses to 
DDAVP administration. Two of his patients were females and it can­
not be excluded that these 'patients' were in fact carriers of the 
NDI gene. Similarly, Moses et al. [20] described a 25-year old 
woman with polyuria and polydipsia and resistance to the antidiu-
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retic action of vasopressin, who had significant vWF-, FVIII-, 
plasminogen activator- and vasodilatory responses to DDAVP. Ohzeki 
et al. [23] reported on a 20-day old Japanese male infant with con­
genital NDI, who demonstrated elevation of FVIII:С and vWF levels 
after administration of arginine vasopressin. 
Several explanations for the divergent renal and extrarenal res­
ponses to DDAVP in our patient can be offered. 
In previous studies, NDI has been divided into two different types 
(type 1 and type 2) in respect to urinary c-AMP responsiveness 
[22,32]. In type I NDI, cAMP excretion showed no definite change 
(<127 % as compared to a 200%-250 % rise in patients with vaso-
pressin-sensitive diabetes insipidus) after stimulation with DDAVP 
(22). DDAVP produced significant increases (mean 1296%) in urinary 
cAMP levels in other cases of NDI, which were diagnosed as type 2 
of the disease (22, 32). In type I, a defect in the production of 
c-AMP in the renal tubular cells has been considered, and in the 
other type in the reception of the c-AMP signal. Although the fin­
ding of normal extrarenal responses to DDAVP in our patient could 
be consistent with a post c-AMP defect being the cause of his re­
nal resistance to vasopressin, this possibility is unlikely be­
cause our patient showed only a 119% rise in urinary c-AMP levels 
in response to DDAVP, without an increase in urinary osmolality. It 
must, however, be admitted that in animal experiments an increase 
of cAMP in medullary tissue is not always reflected by an increase 
in the urinary concentration of cAMP [1]. 
It seems inprobable also that the defect resides at the level of 
the guanine nucleotide regulatory protein (G-protein) that serves 
to couple the receptor to the catalytic moiety of the adenylate 
cyclase complex [28]. In that case, one would expect our patient, 
in analogy with patients suffering from pseudohypoparathyreoidism 
type I [26,27], to be resistant to multiple hormones, whose actions 
are mediated by c-AMP. However, the possibility of a defective G-
protein being the cause of the renal unresponsiveness to vasopres­
sin in our patient can not be excluded completely. Although as yet 
it is thought that the G-proteins involved in adenylate cyclase 
stimulation (G
s
 proteins) are 'house-keeping ' G-proteins, that 
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are expressed in almost every cell [18,21], it seems possible, 
theoretically, that the G-protein implicated in the action of vaso-
pressin in the distal renal tubule is tissue-specific and differs 
from the one that couples the extrarenal V2 receptors to the adeny-
late cyclase system. Tissue-specificity of G-proteins has already 
been demonstrated for transducin, a pertussis toxin-sensitive G-
protein, involved in visual transduction in photoreceptor cells 
[19]. 
It is more likely, however, that the defect is located in the re-
ceptor itself. In that case, the finding of blunted renal but nor-
mal extrarenal responses to DDAVP could be explained by the hypo-
thesis that the antidiuretic receptor is different from the extra-
renal V2 receptors. Conceivably, in our patient only the renal V2 
receptor is involved in the defect, while in most other NDI pa-
tients there is a general V2 abnormality. 
At present the exact site of these extrarenal V2 receptors remains 
to be elucidated. It is unlikely that the receptors are located on 
the endothelium itself, since there is no direct action of DDAVP on 
the endothelial cell [4,29]. Speculations that these V2 receptors 
are situated in the central nervous system and that DDAVP may act 
through release of a putative second messenger [8], have not been 
confirmed [9,13]. 
The finding of normal extrarenal responses to DDAVP in some NDI pa-
tients (including our patient), but absence of these responses in 
others, may reflect phenotypical heterogeneity in NDI. Whether 
there is genetic heterogeneity also can not be decided from our 
data. In recent studies the gene for X-linked NDI has been assig-
ned to distal Xq by demonstrating tight linkage to the Xq28 marker 
DXS52, which is defined by probe Stl4, and to other distal Xq mar-
kers [14,15]. We found that both our patient and his healthy 
brother had inherited the same Stl4 allele from their mother. This 
Stl4 allele came from the maternal grandfather. Since our patient 
is a sporadic case, these observations are inconclusive as to 
whether the disease is due to a mutation in another gene, which is 
not located at distal Xq, or due to a new mutation in the gene lo-
cated at Xq28. 
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7.1 ABSTRACT 
The effects of treatment with the combination amiloride-hydro-
chlorothiazide were compared to indomethacin-hydrochlorothiazide 
treatment, as yet considered to be the most effective treatment, in 
five boys with congenital nephrogenic diabetes insipidus. Amilori-
de-hydrochlorothiazide appeared to be equally effective as 
indomethacin-hydrochlorothiazide on urine volume and urine osmola-
lity values. During the amiloride-hydrochlorothiazide period normo-
kalemia could be maintained without potassium salt supplementation. 
Administration of amiloride-hydrochlorothiazide did not cause un-
desirable side effects. The combination may therefore be at least 
of similar value as the indomethacin-hydrochlorothiazide regimen in 
the treatment of this condition. 
7.2 INTRODUCTION 
Treatment of Nephrogenic Diabetes Insipidus (NDI) has posed a par-
ticularly vexing problem. Thiazide diuretics and prostaglandin syn-
thesis inhibitors were shown to be of important benefit in the 
management of this disease. Several studies l_2-3-4-5 have demon-
strated that the combination of hydrochlorothiazide with the pros-
taglandin synthesis inhibitor indomethacin is the most effective 
therapy at this moment. However, prolonged use of thiazides is fre-
quently complicated by hypokalemia, secondary to renal loss of 
potassium 6, and long-term treatment with prostaglandin synthesis 
inhibitors may have untoward renal and systemic side effects 7 _ 8. 
Therefore, we were interested in finding an alternative therapy 
with the same efficacy as the indomethacin-hydrochlorothiazide 
combination, but without the adverse effects. Recent work has sug-
gested that the combination of hydrochlorothiazide with the potas-
sium-sparing diuretic amiloride could be a satisfactory alterna-
tive 9. In this latter study, however, only two patients with 
hereditary NDI were included, and other systematic studies com-
paring both forms of treatment are as yet not available. 
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The aim of the present study was to compare the effects of the 
indomethacin-hydrochlorothiazide combination with those of the 
amiloride-hydrochlorothiazide regimen in five children with NDI. 
7.3 PATIENTS AND METHODS 
The study was performed in five male patients (aged 5-16 years) 
with congenital NDI from the Netherlands. TVo of them had a posi-
tive family history, the other three were isolated cases. Diagnosis 
of NDI was based on the typical history of polyuria, polydipsia, 
hypematremia, fever, and failure to thrive in the presence of a 
highly diluted urine, and confirmed by the lack of increased urine 
osmolality after infusion of the synthetic vasopressin analogue 1-
desamino-8-D-arginine vasopressin (DDAVP). In all patients serum 
creatinine and creatinine clearance were normal. 
Echography revealed no hydronephrosis, hydroureter, or dilatation 
of the bladder. Acquired causes of NDI and additional tubular dys-
functions were ruled out in each patient. 
All patients were receiving a diet with moderate salt restriction 
and treatment with indomethacin (2 mg/24 hour/kg/)-hydrochloro-
thiazide (2 mg/24 hour/kg), supplemented with oral potassium salt 
[1500 nig/24 hour]) . 
The studies lasted 16 days each and were performed at the pediatric 
metabolic unit of the St.Radboud Hospital of Nijmegen, The Nether-
lands. Informed consent was obtained from the parents and, when 
applicable, from the patients. 
All patients were studied in the same way. A constant diet with 
moderate salt restriction, patterned after the home diet, was 
provided and all patients had free access to water. All intakes 
were recorded. 
The study was divided into three consecutive periods: 
Step I Continuation of the treatment with indomethacin (2 mg/24 
hour/kg) - hydrochlorothiazide (2 ing/24 hour/kg, supple-
mented with oral potassium salt [1500 mg/24 hour]) for 6 
days. 
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Step II Interval of 4 days in which only hydrochlorothiazide 
(2 ing/24 hour/kg, supplemented with oral potassium salt 
[1500 mg/24 hour]) was administered. 
Step III Treatment with amiloride (20 mg/24 hour/1.73m2)-hydro­
chlorothiazide (2 mg/24 hour/kg) for 6 days. 
Each day, blood pressure and body weight were recorded by the me­
dical staff. 24-hour urine was collected daily for measurement of 
volume, osmolality and creatinine. Blood was obtained by venipunc­
ture on days 4, 5, and 6 of steps I and III, for measurement of 
sodium, potassium, creatinine and osmolality. Osmolar clearance 
(C
o s m
) and free water clearance (CH2o) were calculated by con­
ventional formulas: 
c
osm = (uosm x v ) / posm'· CH20 = v " cosm» where U
o s m
 represents 
urine osmolality, Ρ
ο β 1 η plasma osmolality, and V urine volume. 
Data were analyzed for significance by Student paired t-test. The 
significance level was taken at 0.01. 
After the study, the patients were discharged on the combined 
amiloride-hydrochlorothiazide regimen and moderate-salt diet and 
were re-evaluated weekly for the first month and four times a year 
thereafter. 
7.4 RESULTS 
Fig.l presents the data collected in patient no.l. 
The mean values of body weight, serum electrolytes, serum osmo­
lality, glomerular filtration rate (GFR), urine volume, urine 
osmolality, osmolar clearance and free water clearance on days 4, 
5, and 6 during treatment periods I and III are given in Tables 1 
and 2 for each of the five boys. Serum sodium levels were signifi­
cantly lower during the amiloride-hydrochlorothiazide period than 
during the indomethacin-hydrochlorothiazide period. No significant 
differences between the two forms of therapy were found with res­
pect to the values of serum potassium, although in four patients 
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Table 7 .1 Ccnparison of the two forms of treatment an body weight, serum 
e l e c t r o l y t e s , serum osmolality and creat inine clearance in f ive pat ients 
with congenital nephrogenic diabetes ins ipidus . For each pat ient the mean 
values an day 4 , 5 , and 6 are calculated. 
senni 
Ät ient body wsic^it 
(Kg) 
sodiun 
(іпгаІД) 
potassiun 
(raml/l) 
osrolality 
(irosrol/kg) 
GFR 
(mL/tain) 
I 
A 
20.2 
19.6 
141 
136 
4.0 
3.3 
293 
287 
132 
116 
2 
3 
4 
5 
I 
A 
I 
A 
I 
A 
I 
A 
24.5 
25.0 
36.1 
36.2 
49.5 
47.7 
17.4 
16.8 
146 
144 
143 
137 
145 
135 
142 
138 
3.7 
4.0 
4.0 
4.4 
3.8 
3.9 
3.4 
4.7 
292 
287 
295 
280 
295 
275 
289 
291 
125 
117 
88 
96 
89 
95 
126 
103 
p-value n.s. < 0.01 n.s. n.s. n.s. 
I = Ih±itEtiiacirrflidrochlaroöiiazide; A = itailaride-Hydnxhlarothi ДТІІІІР.. 
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Table 7.2 Ccsiparison of the two forms of treatment on urine volume, 
urine osmolality, osmolar clearance (C^g,,), and free water clearance 
(cH2o) i1 1 f i v e pat ients with congenital nephrogenic diabetes insipidus. 
For each pat ient the mean values on day 4,5, and 6 are calculated. 
I&tiert vdkme carolai ity ссвя і^ЕО 
(I/24h) (moatol/kg) (nQ/min) (ml/tain) 
1 
2 
3 
4 
5 
A 
A 
A 
A 
4.0 
3.3 
5.2 
5.2 
2.9 
4.1 
4.5 
5.3 
2.5 
2.0 
129 
125 
113 
126 
282 
227 
113 
137 
139 
IP'S 
1.2 
1.0 
1.4 
1.6 
1.9 
2.3 
1.3 
1.9 
0.8 
0.6 
1.6 
1.3 
2.2 
2.0 
0.1 
0.6 
1.8 
1.8 
0.9 
0.8 
p^value n.s. n.s. n.s. n.s. 
1= IndcBnethacin-Hydrochlorothiazide; A = Amiloride-Hydrochlorothiazide. 
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Fig. 7.1 Illustration of the effects of different forms of treatment 
in patient no.l. 
Sodium 
(mmol/l) 
Potassium 
(mmol/l) 
Osmolality 
(mosmol/kg) 
Weight 
(kg) 
Osmolality 
(mosmol/kg)
e 0 
^^HgODmVmln 
Therapy 
Indomethacin 
(mg/24h/kg) 
Hydrochlorothiazide 
(mg/34h/kg) 
KCl 3000 η 
(mg/24h) 1500 4 
20-1 
ίο Η 
" χ> A v . . .••Λ'.-ΛΑ&.'Λ W A ' ^ V I :OC : ;v.v. л . л . . . ! . . О Л > Л - . О Л У . У . . . 
Amiloride 
(mg/24h/1.73m2) 
* + * + * + + + 
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potassium levels were slightly higher during the amiloride-hydro-
chlorothiazide period. Further comparison between the alternative 
treatments showed that there were no significant differences in the 
patients' body weight, and in serum osmolality, GFR, urine volume, 
urine osmolality, osmolar clearance and free water clearance. 
Follow-up studies of up to 1 year revealed that the patients main-
tained normal serum electrolyte concentrations. Urine volume and 
osmolality remained within the same range as observed during the 
study. No side effects of the amiloride-hydrochlorothiazide com-
bination were observed in four of our patients. In one patient 
amiloride administration had to be interrupted after 6 months 
because of abdominal pain and anorexia. 
7.5 DISCUSSION 
The treatment of NDI has been a problem since the original des-
cription of the disease in 1945 10"11. The first class of drugs 
shown to be relatively safe and clinically useful was the thiazide 
diuretics 12. when combined with a reduction of solute (salt) in-
take, this mode of treatment reduces urine volume by only 20% to 
50% of baseline values, and is therefore not entirely satisfactory. 
In addition, the thiazide-induced kaliuresis may cause further im-
pairment of urine concentrating ability 13, which could exaggerate 
polyuria and polydipsia in patients with NDI. Another possible 
risk, associated with hypokalemia is cardiac arrhythmia •1·4. Thus, 
simultaneous administration of potassium salt is necessary in most 
cases. Potassium supplements may cause severe gastrointestinal 
complications such as ulceration, gastritis, hemorrhage, obstruc-
tion and perforation 15-16-17
 a n ( j f therefore, close supervision is 
necessary. 
Prostaglandin synthesis inhibitors, such as indomethacin 1-2-3-4-5^ 
Ibuprofen 1 8, and acetylsalicylic acid 1 9 have been used for the 
treatment of NDI with encouraging results. Although the exact un-
derlying mechanisms are not known, these agents appeared to have a 
beneficial effect on urinary output, especially when combined with 
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hydrochlorothiazide 2-3-4-5# However, prolonged use of prosta­
glandin synthesis inhibitors is frequently complicated by severe 
side effects in the gastrointestinal, haematopoietic, and CNS-sys-
tems 7 - 0 . Gastrointestinal complaints and complications consist of 
anorexia, nausea, vomiting, abdominal pain, ulceration, perfora­
tion, and hemorrhage. Haematopoietic reactions include neutropenia, 
thrombocytopenia, and, rarely, aplastic anemia. In addition, renal 
dysfunction has been observed during indomethacin therapy, most 
often a transitory reduction in glomerular filtration rate (GFR) 2 -
3 - 4
. Thus, although the high efficacy of the indomethacin-hydro-
chlorothiazide regimen is without doubt, long-term treatment with 
this combination has major disadvantages. 
Alon and Chan 9 demonstrated in two NDI patients that hydrochloro­
thiazide, when combined with the potassium-sparing diuretic amilo-
ride, was at least as effective as the hydrochlorothiazide-prosta­
glandin synthesis inhibitor regimen. A systematic comparison be­
tween these two alternative combinations, however, was only made 
in one patient. 
In the present study the observations by Alon and Chan are extended 
in five NDI patients. Urine volume- and urine osmolality values 
were not significantly different during either regimen, and no dif­
ferences were seen with regard to their effects on osmolar clea­
rance and free water clearance. Serum sodium levels were signifi­
cantly lower with the amiloride-hydrochlorothiazide combination. 
Since the patients' weight and GFR were similar with both treatment 
modalities, this indicates that urinary sodium excretion was at a 
slightly higher level during the amiloride-hydrochlorothiazide 
period than during the indomethacin-hydrochlorothiazide trial. This 
is in agreement with previous studies which have shown that amilo-
ride has natriuretic potency 20-21f whereas indomethacin may pro­
mote salt retention 22-23^ 
The use of amiloride in combination with hydrochlorothiazide in'the 
treatment of NDI has three major advantages, which will be dis­
cussed in the following. 
First, amiloride counterbalances the potassium losses secondary to 
thiazide treatment 24-25-26-27
 a n (j -цщд prevents hypokalemia and 
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the need for potassium salt supplementation. The potassium-sparing 
effect of amiloride was confirmed in our five patients with NDI. 
During the amiloride-hydrochlorothiazide period, there was no need 
for potassium supplementation to maintain normokalemia, in contrast 
to the indomethacin-hydrochlorothiazide regimen. 
Second, the antidiuretic actions of thiazides and amiloride appear 
to be additive 9 - 2 5. Different mechanisms of action within dif-
ferent segments of the distal nephron may provide a basis for the 
additive effects. As demonstrated in microperfusion studies 28-29-
30 and microcatheterization experiments 3 1, thiazides inhibit the 
electroneutral sodium-dependent chloride transport in the "early" 
distal tubule, whereas eimiloride blocks the luminal membrane sodium 
channel in the cortical and medullary collecting duct. Thus, com-
bined administration of amiloride and hydrochlorothiazide results 
in a more marked urinary sodium excretion than either diuretic 
given as a single agent. 
Assuming that the efficacy of thiazides in NDI is related to the 
reduction of extracellular sodium content and, therefore, enhance-
ment of reabsorption in the proximal tubule, as proposed by Early 
and Orloff 3 2 and supported by others 3 3 - 3 4, further augmentation 
of sodium excretion by amiloride might be responsible for the addi-
tive antidiuretic effects of both drugs. 
However, amiloride and hydrochlorothiazide might exert their ef-
fects in NDI also through other mechanisms. In this regard it is 
interesting to note that in vasopressin-deficient rats the anti-
diuretic effect of hydrochlorothiazide was shown to be mediated 
not only by changes in proximal tubular function, but, more im-
portantly, by a rise in inner medullary osmolality, favouring in-
creased water reabsorption form the collecting duct 35. Likewise, 
the antidiuretic effect of amiloride has been shown to be, at least 
in part, independent of increased proximal reabsorption in patients 
with lithium-induced NDI. 3^. Whatever the explanation, the fact 
that the antidiuretic actions of amiloride and hydrochlorothiazide 
are additive is important in the treatment of NDI. simultaneous 
administration of these drugs significantly attenuates obligatory 
urine loss to a tolerable level per day. Such a change in urine 
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flow also prevents the dilatation of the urinary tract. 
Finally, side effects of amiloride are uncommon and less severe 
than those reported for indomethacin, and several studies, inclu­
ding the present one, have indicated that prolonged use of the drug 
in combination with hydrochlorothiazide is usually well tolerated 
9-37-38
φ 
We conclude that the amiloride-hydrochlorothiazide combination is a 
desirable form of therapy for congenital nephrogenic diabetes insi­
pidus. It is equally effective as the prostaglandin synthesis in-
hibitor-hydrochlorothiazide regimen, it prevents the need for 
potassium supplementation, and it has only minor long-term side 
effects. 
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CHAPTER 8 
GENERAL DISCUSSION 
8. GENERAL DISCUSSION 
If not diagnosed and treated early in life, NDI may have serious 
complications such as growth retardation and brain damage, the 
latter resulting in severe mental retardation. Furthermore, the di-
sease may have a serious impact on the social life of families in 
which one or more children are suffering from NDI. 
The study described in this thesis has been undertaken in order [i] 
to search for reliable means of early diagnosis and carrier detec-
tion in X-linked NDI, [ii] to extend our knowledge about the patho-
genesis of the disorder, and finally [iii] to find an alternative 
for the conventional therapy (the combination indomethacin-hydro-
chlorothiazide) of the disease, the latter having major disadvan-
tages. 
The following discussion will be focused on the aspects of diagno-
sis, pathogenesis and therapy of NDI. Finally, an outlook on fur-
ther studies will be given. 
8.1 DIAGNOSIS 
Employing genetic DNA linkage studies in 11 families with NDI, we 
were able to demonstrate tight linkage with the anonymous DNA mar-
kers DXS52, DXS33, DXS15, DXS134, the clotting factor VIII and the 
colour blindness genes, all of which are located at band Xq28 on 
the distal long arm of the human X chromosome (chapter 2, 3, and 
4). The highest lod score (log of odds for linkage versus indepen-
dent assortment given the observed segregation in families) of 
10.35 was obtained with the DXS52 marker, defined by probe Stl4, 
which did not show recombination with the disease gene. This indi-
cates that the odds were 1010:1 in favor of linkage. From these 
results it can be concluded that the distance between the NDI gene 
and the locus DXS52 is less than 5 centiMorgans (cM) (95% confi-
dence limits). This renders the DXS52 marker a valuable tool for 
heterozygote detection and early (prenatal) diagnosis of NDI. In 
addition, multipoint linkage analysis enabled us to construct a 
refined genetic map of the distal part of the long arm of the human 
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X chromosome : Xcen - F9- DXS98 - F8C/CBD,CBP - NDI/DXS52 - DXS134-
Xqter. This map places the NDI gene between the coagulation factor 
VIII gene (F8C) and DXS134. It is worth pointing out that, although 
our analysis maps the F8C gene proximal to the DXS52 locus, their 
is still no consensus on the relative orientation of both genes. 
During the most recent Human Gene Mapping Conference (HGM10, Mandel 
et al., 1989) both studies suggesting that F8C is proximal to DXS52 
(Lehesjoki et al., 1989), and studies suggesting a distal localiza-
tion of F8C with respect to DXS52 (Gross et al., 1989; Vincent et 
al., 1989) have been reported. 
The refined localization of the NDI gene achieved in our study 
should be a major step towards the isolation of this gene by appli-
cation of 'reverse genetics' strategies (Ruddle, 1984; Orkin, 
1986), which will be the purpose of further studies (see Outlook: 
Towards isolation of the NDI gene'). 
8.2 PATHOGENESIS 
It has been demonstrated that patients with X-linked NDI fail to 
show elevated von Willebrand factor (vWF)-, FVIII coagulant acti-
vity (FVIII:C)- and plasminogenactivator levels after administra-
tion of the V2 specific agonist l-desamino-8-D-arginine vasopressin 
(DDAVP) (this study: chapter 5 and 6; Kobrinski et al., 1985; Bi-
chet et al., 1988). In addition, vasodilatory responses to DDAVP 
are absent in NDI patients (this study: chapter 5 and 6; Bichet et 
al., 1988). These findings suggest that the hemodynamic-, coagu-
lation-, and fibrinolytic responses to DDAVP are mediated by acti-
vation of extrarenal V2 receptors and support the concept of a 
general V2 abnormality in NDI. The precise location of the extra-
renal V2 receptors remains to be elucidated. Possible sites are the 
endothelium [the site of synthesis and secretion of plasminogen-
activator (Gerard et al., 1986) and of vWF (Jaffe et al., 1974)], 
the hepatic sinusoids [the site of FVIII synthesis and release 
(Stel et al.,1983)] and the central nervous system (Cash et al., 
1978). 
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It is worth noting that a few patients have been reported, among 
whom the patient (J.B.) described in chapter 6, in which the defect 
seems to be confined to the kidney (Brenner et al., 1988; Moses et 
al., 1988). These patients, however, most probably do not suffer 
from 'classical' NDI but from a variant type of the disease. The 
following discussion will be focused on the 'classical' type of 
NDI. Subsequently, some comments on the variant type of the disease 
will be made. 
As yet, the precise pathogenetic mechanism underlying NDI is unde-
fined. Nevertheless, the results of DDAVP experiments strongly ar-
gue against several of the potential defects dealt with in the 
'Introduction' (1.2.7), as will be discussed below. Moreover, other 
hypothetical sites of the primary defect may be excluded by drawing 
an analogy with pseudohypoparathyreoidism. This disorder results 
from primary resistance to the action of parathormone (PTH) which, 
like vasopressin, acts on the renal tubule by binding to the hor-
mone receptor and subsequently through activation of the adenylate 
cyclase-cAMP system. As to the defects proximal to cAMP formation, 
deficient activity of the guanine nucleotide binding protein (G 
protein) is not very likely. The G-protein involved in adenylate 
cyclase activation is assumed to be similar if not identical in 
most cells (Lochrie and Simon, 1988) (although tissue-specificity 
of G-proteins can not be excluded completely [see chapter 6]). 
Therefore, a defect in this G-protein should lead to resistance to 
multiple hormones that act by stimulating adenylate cyclase. 
Indeed, deficiency of this G-protein has been shown to be the basis 
for multiple hormone resistance in patients with pseudohypoparathy-
reoidism type I (Spiegel et al., 1982; Levine et al., 1983). A de-
fect of the enzyme adenylate cyclase per se, such as has been found 
in a subset of patients with pseudohypoparathyreoidism (Barret et 
al., 1989), can also be excluded by the fact that multiple hormone 
resistance is not observed in NDI. For the same reason it is impro-
bable that an increase in cAMP phosphodiesterase, resulting in ab-
normally high degradation of cAMP, is underlying NDI. 
As to the defects distal to cAMP formation, an abnormality of the 
cAMP-dependent protein kinase can be considered a candidate for 
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causing NDI. The enzyme cAMP dependent protein kinase exists as two 
types (types I and II), which are distinguished by their different 
regulatory subunits (RI and RI I, respectively) whereas the cataly­
tic subunit (С) of both types appear essentially identical (Flock-
hart and Corbin, 1982; Krebs, 1989). It has been demonstrated that 
several unique and antigenetically distinct gene products exist 
within each R-subunit class. Some appear to be expressed in most 
tissues (Lee et al., 1983), while expression of others is tissue-
specific (Jahnsen et al., 1986). An attractive speculation might 
be that an abnormality in a R-subunit, which is specific for the 
tubular cells sensitive to vasopressin, is the cause of NDI. This 
assumption, however, does not explain the absence of extrarenal 
responses to vasopressin in NDI patients. 
In the animal model of NDI lack of insertion of water permeable 
patches into the apical membrane of vasopressin sensitive renal 
cells has been demonstrated (Brown et al., 1985). The observation 
that the resistance to vasopressin in patients with X-linked NDI is 
not confined to the kidney but involves other, extrarenal, tissues 
as well, renders it improbable that the defect in human NDI is 
identical to that found in the experimental disease. 
In a recent study, Bichet et al. (1989) infused epinephrine into 
three male subjects with NDI. Factor VIII and tissue type plasmi­
nogen activities increased by 75 to 100 %, and plasma renin acti­
vity and plasma cyclic AMP by 200 %. None of these values chemged 
when patients received DDAVP. These data strongly argue for an 
altered pre-cAMP mechanism. 
As yet, the most likely explanation for the resistance to vaso­
pressin in NDI is absence or abnormality of the V2 receptor itself. 
In view of the specificity of the different hormone receptors, this 
hypothesis is consistent with the fact that NDI is characterized by 
insensitivity to a single specific hormone. Moreover, the idea is 
compatible with the fact that both renal- and extrarenal V2-media-
ted responses are absent in this disease. 
Whether or not the renal and extrarenal V2 receptors are exactly 
identical remains to be elucidated. In this respect, the finding 
of normal V2-mediated responses to DDAVP in a few 'atypical1 NDI 
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patients is very interesting. It is tempting to speculate that 
these patients have a V2 receptor defect which is limited to the 
kidney and does not include the extrarenal receptors. This assump-
tion can only be valid if the extrarenal receptor is different from 
the renal one. As mentioned in the 'Introduction' (1.2.4), the mam-
malian renal V2 receptor consists of two subunits (Fahrenholz et 
al., 1985). Therefore, it is conceivable that the renal and extra-
renal receptors share one subunit but have different second sub-
units. Thus, the 'classical' type of NDI might be due to a defect 
of the common subunit, resulting in a generalized V2 receptor de-
fect. In the patients with the variant type of NDI, there might be 
lack or a functional defect of the second subunit of the renal 
receptor, resulting in a V2 receptor defect that is confined to 
the kidney. 
Alternatively, the 'atypical' patients may have a defect distal to 
the formation of cAMP. In patient J.B. (chapter 6), this was con-
sidered unlikely (but not excluded) , given the lacking rise of 
urinary cAMP levels in response to DDAVP. In the few other 'aty-
pical' patients reported (Moses et al., 1988; Brenner et al., 
1988), urinary cAMP levels were not measured. 
8.3 THERAPY 
In recent years it has been shown that prostaglandin synthesis in-
hibitors, such as indomethacin, are very useful in the treatment 
of NDI, especially when combined with hydrochlorothiazide (Blachar 
et al., 1980; Monnens et al., 1984; Rasher et al., 1987). The se-
rious disadvantages inherent to the use of the prostaglandin syn-
thesis inhibitor-hydrochlorothiazide regimen, however, led us to 
look for another approach. Based on a recent study, in which the 
value of the combination amiloride-hydrochlorothiazide in the 
treatment of NDI was suggested (Alon and Chan, 1985), we syste-
matically compared the effects of the amiloride-hydrochlorothiazide 
regimen with those of the indomethacin-hydrochlorothiazide com-
bination. We demonstrated that both combinations were equally effi-
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cient in decreasing urine volume and increasing urine osmolality 
(chapter 7). Use of the combination amiloride-hydrochlorothiazide 
has several important advantages. First, amiloride counterbalances 
the potassium losses secondary to prolonged use of thiazides (Alon 
and Chan, 1985; Dyckner et al., 1988) and thus prevents hypokale-
mia. Secondly, the antidiuretic actions of amiloride and hydro-
chlorothiazide appear to be additive (Alon and Chan, 1985; Wilson 
et al., 1988). Different sites of action of both drugs within the 
distal nephron (Fig. 1) may underlie their additive effects (Cos-
tanzo, 1985; Velazquez and Wright, 1986; Ellison et al., 1987; 
Sonnenberg et al., 1987). 
glomerulus 
Fig. 8.1 
Schematic presentation of the different sites of action of thiazides and 
amiloride in the distal nephron. The distal tubule is heterogeneous and 
conprises at least three suocesive segments: the distal convoluted tubule 
(1), the connecting tubule (2), and the initial collecting tubule (3). 
lïüazides act an the distal convoluted tubule (the 'early' distal tu-
bule), idiile amiloride acts on the initial collecting tububle (the 
'late' distal tubule) and on the cortical and medullary collecting duct. 
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Finally, several studies, including the present one, have indicated 
that the amiloride-hydrochlorothiazide regimen has only minor long 
term side effects. 
Taken together, the combination amiloride-hydrochlorothiazide may 
be a satisfactory alternative to the prostaglandin synthesis inhi-
bitor-hydrochorothiazide regimen in the treatment of NDI. 
8.4 OUTLOOK: TOWARDS ISOLATION OF THE NDI GENE 
For most of the genes that have been cloned to date, isolation was 
possible because of their known metabolic function or because the 
purified gene product was available. However, most human single 
gene disorders, including NDI, result from mutations in genes whose 
normal function is unknown. In the absence of a characteristic 
metabolic disorder or a specific functional test, the most pro-
mising approach to elucidating such gene defects is the use of 
'reverse genetics' strategies (Ruddle, 1984; Orkin, 1986; Ropers, 
1987). In this approach the isolation of the respective disease 
gene relies solely on its chromosomal location. Reverse genetics 
strategies have been applied succesfully for cloning the Duchenne 
Muscular dystrophy (DMD) gene (Monaco et al., 1986; Burghes et al., 
1987; Koenig et al., 1987), the chronic granulomatous disease (CGD) 
gene (Royer-Pokora et al., 1986), the retinoblastoma (Rb) gene 
(Friend et al., 1986; Lee et al., 1987) and, most recently, for 
isolation of the gene responsible for cystic fibrosis (Riordan et 
al., 1989; Rommens et al., 1989). 
The detailed information on the subchromosomal localization of the 
NDI gene obtained in our study makes it potentially feasible to 
approach the isolation of the gene itself in a similar fashion. 
Alternatively, in view of the evidence that a defect in the V2 
receptor may be the primary cause of NDI, cloning strategies might 
involve functional assays for presence of this receptor. In the 
following section both approaches will be discussed in some detail. 
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Reverse genetics approach 
The first crucial step to identify and clone genes using the rever­
se genetics approach is to establish the exact map position of the 
gene involved. Our linkage analyses have placed the NDI gene in the 
Xq28 region within 5 CM from the most closely linked marker DXS52 
(Knoers et al., 1988a [chapter 2], 1988b [chapter 3], 1989 [chap­
ter 4]). The genetic length of the entire human genome, about 3000 
cM, corresponds to a physical length of around 3 χ IO9 bp. Although 
cross-overs are not evenly distributed in the human genome 
(Saadallah and Hulten, 1983), 5 cM should on average represent 
about 5 χ 10 6 bp, which is an enormous distance in molecular gene­
tic terms. Moreover, it is not yet known whether the NDI gene is 
located proximal or distal to the DXS52 locus. 
Therefore, further definition of the chromosomal region carrying 
the NDI gene will require additional linkage studies, using new DNA 
markers from the Xq28-qter region, which have recently become avai­
lable. The number of available NDI families will ultimately limit 
the precision with which genetic distances and the gene order in 
the NDI region can be determined. In general, linkage analysis 
alone will get us not much closer than 1 cM from the disease gene. 
Even a physical distance of 10 6 bp (which corresponds, on average, 
to a genetic distance of 1 cM) is too large to be bridged by stan­
dard molecular techniques. 
The length of region easily analyzed by conventional techniques has 
until recently been limited by the capacity of available cloning 
vectors (<40 kb) . In addition, the resolution of conventional gel 
electrophoretic methods is only adequate for fragments of about 
20.000 base pairs or smaller. To bridge the gap between genetic and 
physical mapping approaches the techniques of pulsed field gel 
electrophoresis (PFGE) (Schwartz and Cantor, 1984; Carle and Olson, 
1984; van Ommen and Verkerk, 1986), field inversion gel electropho­
resis (FIGE) (Carle et al., 1986) or contour-clamped homogeneous 
electric field (CHEF) electrophoresis (Chu et al., 1986) can be 
employed. These methods are capable of resolving DNA fragments up 
to ten million base pairs by periodicallly altering the direction 
of the electric field. Used together with methods for cutting DNA 
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into large fragments (van Ommen and Verkerk, 1986), these techni-
ques allow the construction of a long range physical map that en-
compasses the gene of interest. Moreover, PFGE is ideally suited 
for the detection of disease-associated microdeletions. Submicros-
copic deletions have been found in a number of X-linked disorders 
(Wieringa et al., 1985; Gal et al., 1986; Cremers et al., 1987) and 
have been a great asset for the molecular and genetic characteri-
zation of several genes (Monaco et al., 1986; Royer-Pokora et al., 
1986; van Ommen et al., 1986; Page et al., 1987). 
With the Identification of very closely linked markers or micro-
deletions it should be possible to clone the entire region con-
taining the disease gene by employing 'chromosome walking' and 
'jumping' techniques. 
'Chromosome walking' (Bender et al., 1983) consists of the itera-
tive screening of genomic (phage or cosmid) libraries to isolate, 
in sequential steps, overlapping DMA clones that together span up 
to several 100 kb of chromosomal DNA. At present, the capacity of 
the available cloning vectors (phages or cosmids) limits the dis-
tances that can be analyzed by walking techniques. On average, the 
new cosmid clones will only contain 20 kb of additional DNA and 
the maximum distance covered per step will be less than 40 kb. 
Therefore, this approach is essentially unsuitable for covering 
large distances. Moreover, the method has no directionality: there 
is an equal chance of walking away from or towards the NDI gene. 
In order to move along chromosomes rapidly, an elegant strategy has 
been developed called 'chromosome jumping' or 'hopping' (Collins 
and Weissman, 1984). In this approach distances of 50-500 kb can be 
covered in a single cloning step. This is achieved by first liga-
ting very large genomic restriction fragments into covalent DNA 
circles containing a selectable marker at the junction site. 
Thereafter, the DNA circles are digested with a restriction enzyme 
that does not cleave the marker sequence, and the resulting frag-
ments, carrying both ends of the original long genomic DNA se-
quence, as well as the selectable marker, are cloned into conven-
tional phage vectors. Using this type of protocol various libra-
ries have been constructed (Poustka and Lehrach, 1986; Collins et 
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al., 1987; Poustka et al., 1987) which allow hopping along a chro-
mosome to move rapidly from a linked marker to a disease gene. 
Concepts have been devised to pre-determine the direction of chro-
mosome hopping. 
A recent, promising approach which dramatically extends the limit 
of contiguously clonatole DNA (from 40 kb to 500-1000 kb or more) is 
the development of yeast artificial chromosome (YAC) cloning (Burke 
et al., 1987). This will simultaneously deviate the problems of 
'chromosome walking' (tedious and sequential) and 'hopping' (loss 
of intermediate DNA). In combination with the reduced complexity 
cell hybrid techniques (see below), it will make the 'wholesale' 
cloning of a target region conceivable. 
In addition to molecular genetic techniques, the use of somatic 
cell techniques (Ruddle et al., 1981) may help to further define 
and isolate the chromosome segment that carries the NDI gene. 
Somatic cell hybrid cell lines containing various portions of the 
telomeric part of the X chromosome long arm will help to order DNA 
markers in the region of interest. For this purpose, we can make 
use of a human-hamster hybrid cell line (908K1B17), which contains 
-as the only human material- the centromeric region of chromosome 
19 and the distal long arm of the X chromosome (Schonk et al., 
1989). This cell line has been constructed by irradiation-induced 
breakage (Goss and Harris, 1975) of a parental cell hybrid (908K1) 
carrying a X/19 translocation. Pilot studies have already shown 
that this cell line carries all DNA markers that are tightly linked 
to NDI and has lost the more proximal markers which are only loose-
ly linked to NDI. 
Further fragmentation of the distal part of Xq into separable sub-
segments is possible through improved irradiation-based protocols 
(Benham et al., 1989). Where these subsegments include the NDI 
region, a complete molecular analysis will be possible. 
With the somatic cell genetic and the molecular approaches des-
cribed above, it should be possible to isolate the entire region 
in which the NDI locus resides, but without specific biological 
tests identification of the recombinant DNA clone carrying the 
relevant genetic information is still very tedious. In genomic DNA, 
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the compound of non-coding sequence significantly exceeds that of 
coding sequence (the exons). To identify expressed sequences in a 
collection of cloned probes, at least two approaches are possible. 
The first one is based on the expectation that exons are more 
stringently conserved during evolution than non-coding sequences. 
Therefore, exons can be isolated by identifying non-repetitive DNA 
segments within the cloned region that detect homologous sequences 
in DNA from other mammalian or vertebrate species. In this way, 
candidate genes for portions of the DMD gene (Monaco et al., 
1986), for the CGD gene (Royer-Pokora et al., 1986), for the Rb 
gene (Friend et al., 1986), and very recently for the cystic 
fibrosis gene ( Rommens et al., 1989) have been isolated. A second 
strategy to detect expressed sequences is based on the knowledge 
that many vertebrate genes are preceeded by DNA sequences that are 
rich in the non-methylated CG dinucleotides (Bird et al., 1986). 
These sequences, known as 'HTF islands1 (Hpall tiny fragment), have 
a length of between 500 and 2000 bp, and often include the first 
exons as well as upstream sequences 5' to the associated gene. GC-
rich 'HTF islands' can be easily detected because, in contrast to 
most other human DNA sequences, they will be cleaved by many rare 
cutting restriction enzymes that contain CG dimers in their recog-
nition sequence. This approach has been employed in an attempt to 
identify the gene responsible for cystic fibrosis (Estivili et al., 
1987) . 
Once a candidate gene has been isolated, definite proof for its in-
volvement in the etiology of NDI must then come from studies demon-
strating lack or aberrant expression of this gene in NDI patients. 
Rapid analysis of mutant genes is now possible using the new Poly-
merase Chain Reaction (PCR) technique (Saiki et al., 1985), a pro-
cedure in which specific DNA segments are amplified enzymatically 
in vitro by DNA polymerase, making use of short synthetic DNA 
primers that flank the region of interest. 20 to 30 PCR cycles 
allow to amplify the number of relevant DNA sequences several 
million-fold in a few hours, thereby enabling their direct mole-
cular (and sequence) analysis. 
Thus, with the PCR procedure it is possible to rapidly amplify the 
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relevant genes from genomic DNA of patients and to screen this DNA 
for deletions or point mutations. 
The "functional approach" 
Conventional methods for cloning the V2 receptor require purifi-
cation of the receptor and identification of the amino-acid se-
quence, either in whole or in part, of the receptor protein(s). 
Then, oligonucleotides corresponding to short stretches of the 
amino acid sequence can be used as probes to screen cDNA or genomic 
libraries for recombinant clones that contain homologous sequences. 
These oligonucleotides can also be used as potential primers for 
the synthesis of highly enriched cDNA. Alternatively, if antibodies 
specifically directed to the receptor protein(s) were available, 
these could be used as probes to screen expression libraries for 
suitable recombinant clones (Young and Davis, 1983). Unfortunately, 
however, neither of these approaches is feasible for the cloning of 
the NDI gene because the structure of the V2 receptor remains to 
be elucidated and suitable antibodies are not available yet. 
Very recently, an interesting observation was made, which may pro-
vide the basis for an alternative cloning strategy. Using a func-
tional assay, based on the increase of intracellular cAMP after 
addition of vasopressin in the medium, V2 receptor activity was 
measured in the 908K1B17 somatic cell hybrid line (see earlier), 
which contains the distal part of the long arm of the human X chro-
mosome, but not in Chinese hamster parental cells which served as 
controls (Dr. F. Fahrenholz, personal communication). On the basis 
of this observation, it should be possible to devise cloning and 
transfection protocols to enrich for and isolate genomic sequences 
that encompass the NDI gene. If succesful, further functional proof 
for the identity of the genes isolated in this way could then come 
from complementation assays, using a cell line deficient in vaso-
pressin binding (for instance, the mutant pig kidney cell line iso-
lated by Fahrenholz and co-workers [Jans et al., 1986]). Experi-
ments along this line are in progress. 
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SUMMARY 
The studies reported in this thesis were undertaken with the aim of 
finding reliable means of early diagnosis and carrier detection of 
NDI and in order to increase our understanding of the pathogenesis 
of this disorder. In addition, in view of the disadvantages of the 
conventional therapy of NDI, an alternative regimen was tested for 
its efficiency and safety. 
The 'Introduction' (chapter 1) summarizes the literature available 
on the clinical picture of NDI, its history, definition and clini-
cal manifestation, diagnosis, genetics, and treatment. Subsequent-
ly, as a prerequisite for a discussion of the potential pathophy-
siological mechanism(s) involved in NDI, an extensive review of 
the literature on the normal water handling is presented. Attention 
is paid to the antidiuretic hormone (vasopressin) release, the 
generation and maintenance of an osmotic gradient in the medullary 
interstitium, and the modulation of water and solute transport by 
vasopressin. 
A brief survey of the extrarenal effects of vasopressin and a des-
cription of an animal model for NDI have been included. 
Thereafter, possible pathophysiological mechanisms that could un-
derly the renal unresponsiveness to vasopressin in NDI are of-
fered. 
The results of DNA linkage studies with various X-linked restric-
tion fragment length polymorphisms (RFLPs) are presented in the 
chapters 2, 3, and 4. By performing two-point linkage analysis in 
NDI families (chapter 2 and 3) we were able to demonstrate tight 
linkage between the NDI gene and the DNA marker loci DXS52, DXS15, 
F8C, and DXS134, all of which are located within band Xq28. These 
results have assigned the NDI gene to the subtelomeric region of 
the X chromosome long arm. By employing three-point linkage ana-
lysis with six DNA markers from the Xq28 region (chapter 4) we were 
able to define the position of the NDI locus more precisely and to 
construct a genetic map of the Xq28 region. 
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The closely linked DNA markers, that have been identified in this 
study provide a valuable tool for reliable carrier detection and 
early (prenatal) diagnosis. In addition, the refined genetic map-
ping of the NDI locus may pave the way towards isolating the gene 
itself. 
The hemodynamic, coagulation, and fibrinolytic responses to admini-
stration of the specific V2 agonist l-desamino-8-D-arginine vaso-
pressin (DDAVP) in NDI patients and normal controls are presented 
in the chapters 5 and 6. In normal controls, significant increases 
in vWF:ag- and plasminogenactivator levels, and considerable vaso-
dilatory responses were observed directly after DDAVP infusion. 
None of these changes were seen in NDI patients, with the exception 
of one patient (J.B.) who exhibited completely normal responses 
(chapter 6). The results confirm that the DDAVP-induced changes in 
hemodynamic, coagulation, and fibrinolytic parameters depend on 
extrarenal V2 receptor activation and support the concept of a 
general V2 receptor defect in NDI. It is suggested that patient 
J.B. may have a variant type of the disease, in which the V2 
abnormality is confined to the kidney. 
In addition, fibrinolytic parameters were examined in female NDI 
carriers (chapter 5) . Responses were rather variable. It is con-
cluded that DDAVP tests are of limited use for the detection of 
NDI carriers. 
The combination of indomethacin-hydrochlorothiazide is, as yet, the 
most effective form of therapy. Prolonged use of this combination, 
however, has several important disadvantages. In chapter 7, studies 
are presented that compare the effects of the indomethacin-hydro-
chlorothiazide therapy with those of an alternative regimen, the 
combination of amiloride-hydrochlorothiazide. Both combinations 
appeared to be equally effective in reducing urine volume and 
increasing urine osmolality. Because of several advantageous as-
pects of amiloride-hydrochlorothiazide therapy, we conclude that 
this regimen can be a satisfactory alternative to the indometha-
cin-hydrochlorothiazide combination in the treatment of NDI. 
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In the general discussion (chapter 8) the importance of the loca-
lization of the NDI gene for diagnostic purposes is emphasized. As 
to the pathogenesis of NDI, it is concluded that absence or defec-
tive functioning of the V2 receptor forms the most likely expla-
nation for the renal (emd extrarenal) unresponsiveness to vaso-
pressin. 
Finally, an outlook is given on the isolation of the NDI gene, 
which should lead to elucidation of the biochemical defect under-
lying NDI. 
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SAMENVATTING 
Dit proefschrift is gewijd aan een aantal aspecten van de con-
genitale, geslachtsgebonden nierziekte Nefrogene Diabetes Insi-
pidus (NDI). De studie had ten doel een betrouwbare methode voor 
vroegdiagnostiek te vinden en een beter inzicht te verkrijgen in de 
Pathogenese van de stoornis. 
Gezien de nadelen verbonden aan de huidige behandeling van NDI werd 
bovendien een alternatieve therapievorm op zijn efficiëntie en 
veiligheid getest. 
In de Inleiding (hoofdstuk 1) wordt een literatuuroverzicht gegeven 
van de klinische aspecten van NDI. Geschiedenis, definitie en Symp-
tomatologie, diagnostiek, erfelijkheid, en behandeling worden ach-
tereenvolgens besproken. 
Vervolgens wordt aandacht besteed aan het normale concentratie-
mechanisme van de nier, omdat inzicht in dit proces noodzakelijk 
is voor de bespreking van de mogelijke pathofysiologische oorzaken 
van NDI. Behandeld worden de afscheiding van Vasopressine uit de 
hypofyse, de opbouw en het behoud van een osmotische gradiënt in 
het niermerg, en de invloed van Vasopressine op de water- en zout-
huishouding van de nier. Een korte schets van de extrarenale ef-
fecten van Vasopressine en een beschrijving van een diermodel van 
NDI zijn aan dit hoofdstuk toegevoegd. 
Daarna worden de pathofysiologische mechanismen die ten grondslag 
zouden kunnen liggen aan de ongevoeligheid voor Vasopressine in NDI 
vermeld. 
De resultaten van DNA-koppelingsstudies met verschillende X-
gebonden restrictie fragment lengte Polymorphismen (RFLPs) worden 
gepresenteerd in de hoofdstukken 2, 3 en 4. Door middel van twee-
punts koppelingsanalyses (hoofdstukken 2 en 3) werd nauwe koppe-
ling aangetoond tussen het NDI-gen en de DNA merkgenen DXS52, 
DXSI5, F8C, en DXS134, die alle in band Xq28 gelokaliseerd zijn. Op 
grond van deze bevindingen kon het NDI-gen worden toegewezen aan 
het subtelomere gebied van de lange arm van het X-chromosoom. Met 
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behulp van drie-punts koppelingsanalyses met 6 DNA merkgenen gelo-
kaliseerd in de Xq28-regio (hoofdstuk 4) kon de positie van het 
NDI-gen nog nauwkeuriger worden bepaald en kon een genetische kaart 
van het Xq28-gebied worden geconstrueerd. 
De nauw gekoppelde DNA merkgenen, die in deze studie geïdentifi-
ceerd zijn, verschaffen ons waardevolle instrumenten voor de her-
kenning van draagsters en voor vroege (prenatale) diagnostiek. De 
nauwkeurige lokalisatie van het NDI-gen is een eerste stap op weg 
naar de isolatie van het gen zelf. 
De hemodynamische-, stollings- en fibrinolytische effecten in NDI-
patiënten en normale controlepersonen na toediening van de speci-
fieke V2 receptoragonist l-desamino-8-D-arginine Vasopressine 
(DDAVP) worden gepresenteerd in de hoofdstukken 5 en 6. Signifi-
cante toename in vWF:ag- en plasminogeenactivatorspiegels en een 
duidelijke vasodilatoire reactie werden waargenomen in normale 
personen direct na DDAVP infusie. Bij NDI-patiënten bleven de 
hemodynamische-, stollings- en fibrinolytische parameters na toe-
diening van DDAVP echter ongewijzigd. Een patiënt (J.B.) vormde 
daarop een uitzondering (hoofdstuk 6). 
De resultaten bevestigen dat de door DDAVP geïnduceerde verande-
ringen in hemodynamische-, stollings-, en fibrinolytsiche para-
meters worden gemedieerd door extrarenale V2 receptoractivatie. De 
bevindingen zijn in overeenstemming met de hypothese dat de V2 
receptorafwijking in NDI gegeneraliseerd is. Er wordt gesuggereerd 
dat patiënt J.B. zou kunnen lijden aan een variant type van de 
ziekte9 waarin de V2 receptorafwijking beperkt is tot de renale 
tubuli. 
Tevens werden de fibrinolytische parameters na DDAVP toediening 
gemeten in draagsters van het NDI-gen (hoofdstuk 5) . De reacties 
waren buitengewoon variabel. Er wordt geconcludeerd dat DDAVP 
testen slechts van beperkte waarde zijn voor de opsporing van NDI-
draagsters. 
Op dit moment is de combinatie indomethacine-hydrochlorothiazide de 
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meest effectieve vorm van therapie voor NDI. Er zijn echter belang-
rijke nadelen verbonden aan langdurig gebruik van deze combinatie. 
In hoofdstuk 7 worden de effecten van de combinatie indomethacine-
hydrochlorothiazide vergeleken met die van een alternatief regime, 
de combinatie amiloride-hydrochlorothiazide. De resultaten laten 
zien dat de combinatie amiloride-hydrochlorothiazide van even 
grote waarde kan zijn in de behandeling van NDI als de combinatie 
indomethacine-hydrochlorothiazide. De voordelen van gebruik van 
amiloride-hydrochlorothiazide worden beschreven. 
In de einddiscussie (hoofdstuk 8) worden de bevindingen van deze 
studies besproken. Het belang van de lokalisatie van het NDI-gen 
voor diagnostische doeleinden wordt benadrukt. Wat de Pathogenese 
van NDI betreft, wordt geconcludeerd dat afwezigheid of een af-
wijking van de V2 receptor zelf de meest waarschijnlijke verkla-
ring vormt voor de renale (en extrarenale) ongevoeligheid voor 
Vasopressine in deze ziekte. 
Tot slot wordt aangegeven welke wegen bewandeld kunnen worden om te 
geraken tot isolatie van het NDI-gen, en daarmee tot ontrafeling 
van het biochemische defect. 
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STELLINGEN behorend bij het proefschrift 'Nephrogenic Diabetes 
Insipidus' van V.V.A.M. Knoers. 
I 
De nauwkeurige lokalisatie van het gen voor Nefrogene 
Diabetes Insipidus in de Xq28-regio is een eerste 
belangrijke stap op weg naar de isolatie van dit gen. 
Dit proefschrift 
II 
De renale (en extrarenale) ongevoeligheid voor arginine 
Vasopressine in congenitale Nefrogene Diabetes Insipidus 
wordt hoogst waarschijnlijk veroorzaakt door een 
gegeneraliseerd Va-receptor defect. 
Dit proefschrift 
lil 
Ten onrechte beweerden Block et al. dat de Vasopressine V2-
receptor ook op mononucléaire fagocyten aanwezig is. 
Block, L.H., et al., J. Clin.Invest. 68:374-381, 1981 
Eigen waarneming 
IV 
De bindingskarakteristieken (maximaal aantal bindings-
plaatsen [1] en affiniteit voor Vasopressine [2]) van Vi-
receptoren op bloedplaatjes in patiënten met Nefrogene 
Diabetes Insipidus (NDI) zijn identiek aan die van de 
plaatjesreceptoren in controlepersonen. Dit impliceert de 
aanwezigheid van intacte
 л
-receptoren in NDI. 
Eigen waarneming 
V 
Het verschijsel Polydipsie mag pas dan als psychogeen 
worden beschouwd wanneer alle overige mogelijke oorzaken 
zijn uitgesloten. 
VI 
Bij kinderen met een bijnierinsufficiëntie dient steeds de 
diagnose adrenoleukodystrofie overwogen te worden. 
O'Neill, В.P., et al. Neurol. .32:543-547, 1982 
VII 
Met behulp van de positron emissie tomografie (PET-scan) 
kan enig inzicht worden verkregen in het pathofysiologisch 
mechanisme dat ten grondslag ligt aan onbegrepen cerebrale 
verschijnselen zoals chorea. 
Hosokawa, S., et al. J.Neurol.Neurosurg.Psych. 50:1284-
1287, 1987 
VIII 
Het meest waarschijnlijke produkt van een 45,X/46,XY 
zwangerschap is een fenotypisch normale jongen. 
Chang, H.J., et al. Am.J.Hum.Genet. 46:156-167, 1990 
IX 
De fenotypisch sterk verschillende Prader Willy en Angelman 
syndromen worden waarschijnlijk veroorzaakt door deletie 
van één en hetzelfde gen op chromosoom 15. 
X 
Van demokratie in het ziekenhuis is pas dan sprake wanneer 
de directie elke vier jaar op een ргодгалта gekozen zou 
worden. 
XI 
De geringe animo onder artsen om zich te specialiseren tot 
neonatoloog is mogelijk te wijten aan de slechte werk­
omstandigheden. 
XII 
Aangezien assistenten in opleiding (AIO's) gedurende de 
vier jaar, waarin zij geacht worden te promoveren, zwaar 
onderbetaald worden, wordt hen aangeraden hun proefschrift 
in de vorm van een syllabus uit te geven. 


